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The present Ph.D. project was divided into different work parts, in a way 
that helps to understand and define the goals of this project. In particular: 
I) Design, synthesis and evaluation of antiviral activity of Arbidol analogs. 
II)  Evaluation of mechanism of Arbidol anti-influenza action. 
III) Synthesis and characterization of a P.E.T. radiotracer for tumor hypoxia: 
1- (5- [18F] Fluoro-5-deoxy-α-D-arabinofuranosyl) -2-nitroimidazole or 
18
F-FAZA. 
The initial research activity concerned the design and synthesis of indole 
derivatives using as a lead compound Arbidol (ARB), a compound that exerts 
immunomodulatory, antioxidant, antiviral and antimetastatic effects
1
. ARB is 
a Russian-made potent broad-spectrum antiviral with demonstrated activity 
against a number of enveloped and non-enveloped viruses, and pH-dependent 
and pH-independent viruses. It exhibits  antiviral activity against a number 
of viruses including influenza A (H1N1, H2N2 and H3N2), B and C viruses, 
respiratory syncytial virus (RSV), adenovirus type 7, coxsackie B3 virus, 
parainfluenza type 5 and rhinovirus type 14, avian coronavirus, infectious 
bronchitis virus and Marek disease virus, hepatitis B virus and hepatitis C 
virus. The wide spectrum of ARB‘s activity suggests that ARB targets 
common critical step(s) in virus – cell interaction. Several studies have shown 
that the affinity of ARB for lipid membranes could account for its antiviral 
actions, together with a differential level of interaction with key motifs in 
glycoproteins of different viruses. Its antiviral activity toward viruses is due 
probably to a direct effect of ARB on virus-cell membrane interactions where 
ARB intercalates into membranes and induces membrane alterations. This 
leads to excessive stabilization of cell membranes, which become resistant to 
virus fusion and in some cases (HCV) to virus replication
2-4
. The known 
biological properties of Arbidol led us to focus on its derivatives as potential 
antiviral agents. In order to maintain antiviral activity we preserved the groups  
responsible of Arbidol interaction with membranes (indole ring, S-phenyl 
group, ester group and amino group) eliminating those that were not 
considered pharmacophores (hydroxy and bromo groups at the 5- and 6-
positions of the indole ring). Moreover we introduced different substituents at 
the 2- and 5-position of the indole ring to investigate the influence of these 
variations on antiviral activity. The synthesis of Arbidol derivatives has been 
established through the validation of two synthetic schemes. Then, to evaluate 
anti-HCV and anti-HSV activity of synthesized compounds, biological assays 
were made. ARB derivatives showed antiviral activity comparable and, in 
some cases, even better than those of lead Arbidol, on both systems. In 
particular, it was shown that synthesized compounds are fusion inhibitors on 
both viruses and also non-selective inhibitors of HCV replication.  
The second part of the present research project concerned the study of 
mechanism of  Arbidol anti-influenza action. There are experimental 
evidences that ARB does not affect viral neuraminidase (NA, a surface protein 
of influenza virus) activity. It affects early post-adsorption stages of virus 
replication with possible involvement of the second surface viral protein, the 
haemagglutinin (HA). Arbidol could act increasing influenza virus HA 
stability and preventing low pH induced HA transition to its fusogenic state, 
thus blocking infection at the viral fusion stage
5
. To support this hypothesis, 
the interaction of Arbidol with the N-terminal hydrophobic fusion domain of 
haemagglutinin (HA) was evaluated. Therefore, the peptide host-guest 
(P20H6) was synthesized using techniques of Solid Phase Peptide Synthesis (SPPS) and 
Circular dichroism studies were made
6
. From these studies we 
demonstrated  that Arbidol interacts with the haemagglutinin fusion domain at 
pH 5 and 7, through changes in the secondary structure of peptide.  
At the end of present Ph.D. project, I spent six months at the University of 
Aberdeen where I worked to the synthesis of a PET (Positron Emission 
Tomography) radiotracer for tumour hypoxia: the [
18
F]1-α-D-(5-Fluoro-5-




F-FAZA is currently the gold standard for PET Imaging of diseases 
characterized by hypoxia (solid tumours, ischemia, stroke)
7
, but it is not 
routinely used and synthesized in Scotland. The work done is an important 
starting point for the introduction of  
18
F-FAZA in Scotland with the aim of 
using it in clinical imaging and research. In particular, following a detailed 
bibliography research on this compound and its synthesis, that is not fully 
reported, and a subsequent optimization of the synthetic scheme used, the 
18
F-
FAZA precursor was obtained: 1-α-D-[5’-O-Toluenesulfonyl-2’,3’-Di-
Oacetylarabinofuranosyl]-2-nitroimidazole (DAcTs-AZA).  
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Chapter 1                                                                                                    Introduction 




The word virus is from the Latin virus referring to poison and other noxious 
substances, first used in English in 1392
1
. A virus (Fig.1.1) is a small 
infectious agent that can replicate only inside the living cells of organisms. 
Most viruses are too small to be seen directly with a light microscope. Viruses 
infect all types of organisms, from animals and plants to bacteria and archaea
2
. 
They are found in almost every ecosystem on Earth and are the most abundant 





Figure 1.1:  Virus. 
 
Despite continuing advances, established and emerging viruses remain major 
causes of human disease, with dramatic costs in mortality, morbidity and 
economic terms. In addition to acute diseases, viruses cause at least 15–20% 
of human cancers and are implicated in neurological and other chronic 
disorders. One of many challenges in controlling viruses and virus-mediated 
diseases is that viruses show an amazing diversity in basic characteristics and 
life cycles, including differences in virion structure, replication strategies, 
genetic organization, gene expression and many other fundamental processes. 
Therefore, even the very processes against which antivirals are targeted often 
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1.1.1 Discovery 
Viral diseases such as rabies have affected humans for many centuries. 
There is hieroglyphical evidence of Polio in the ancient Egyptian empire. 
However, the cause of these diseases was discovered relatively recently.  
In 1717, Mary Montagu, the wife of an English ambassador to the Ottoman 
Empire, observed local women inoculating their children against Smallpox.  
In the late 18th century, Edward Jenner observed and studied Miss Sarah 
Nelmes, a milkmaid who had previously caught Cowpox and was 
subsequently found to be immune to Smallpox, a similar, but devastating 
virus. Jenner developed the first vaccine, based on these findings, and 
smallpox is currently all but wiped out. 
In the late 19th century Charles Chamberland (known today as the 
Chamberland filter or Chamberland-Pasteur filter) developed a porcelain 
filterwith pores smaller than bacteria. Thus, he could pass a solution 
containing bacteria through the filter and completely remove them from the 
solution (Fig. 1.2)
6
. This filter was used to study the first documented virus, 
tobacco mosaic virus. Shortly afterwards, Dimitri Ivanovski published 
experiments showing that crushed leaf extracts of infected tobacco plants were 





Figure 1.2:  Filtration of a mixture of bacteria and viruses. 
 
At about the same time, several others documented filterable disease-causing 
agents, with several independent experiments showing that viruses were 
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different from bacteria, yet they could also cause disease in living organisms. 
These experiments showed that viruses are orders of magnitudes smaller than 
bacteria. The term virus was coined by the Dutch microbiologist Martinus 
Beijerinck. He observed that the agent multiplied only in cells that were 
dividing, but as his experiments did not show that it was made of particles, he 
called it a contagium vivum fluidum (soluble living germ) and re-introduced 
the word virus
8-10
. Beijerinck maintained that viruses were liquid in nature, a 
theory later discredited by Wendell Stanley. 
Since the initial discovery of tobacco mosaic virus by Martinus Beijerinck in 
1898,
[2]
 about 5,000 viruses have been described in detail
11
, although there are 
millions of different types
12
.  
In 1957, equine arterivirus and the cause of bovine virus diarrhea (a 
pestivirus) were discovered. In 1963, the hepatitis B virus was discovered by 
Baruch Blumberg
13
, and in 1965, Howard Temin described the first retrovirus. 
Reverse transcriptase, the key enzyme that retroviruses use to translate their 
RNA into DNA, was first described in 1970, independently by Howard Martin 
Temin and David Baltimore
14
. In 1983 Luc Montagnier's team at the Pasteur 





The origins of modern viruses are not entirely clear, and there may not be a 
single mechanism of origin that can account for all viruses. As viruses do not 
form fossils, molecular techniques have been the most useful means of 
hypothesising how they arose
16
. These techniques rely on the availability of 
ancient viral DNA or RNA, but, unfortunately, most of the viruses that have 
been preserved and stored in laboratories are less than 90 years old. There are 
three main hypotheses that try to explain the origins of viruses
17,18
:  
 Regressive hypothesis: Viruses may have once been small cells that 
parasitised larger cells. Over time, genes not required by their parasitism 
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were lost. The bacteria rickettsia and chlamydia are living cells that, like 
viruses, can reproduce only inside host cells. They lend support to this 
hypothesis, as their dependence on parasitism is likely to have caused the 
loss of genes that enabled them to survive outside a cell. This is also called 
the degeneracy hypothesis. 
 Cellular origin hypothesis: Some viruses may have evolved from bits of 
DNA or RNA that "escaped" from the genes of a larger organism. The 
escaped DNA could have come from plasmids (pieces of naked DNA that 
can move between cells) or transposons (molecules of DNA that replicate 
and move around to different positions within the genes of the cell)
19
. 
Once called "jumping genes", transposons are examples of mobile genetic 
elements and could be the origin of some viruses. They were discovered in 




 Coevolution hypothesis: Viruses may have evolved from complex 
molecules of protein and nucleic acid at the same time as cells first 
appeared on earth and would have been dependent on cellular life for 
billions of years. Viroids are molecules of RNA that are not classified as 
viruses because they lack a protein coat. However, they have 
characteristics that are common to several viruses and are often called 
subviral agents
21
. Viroids are important pathogens of plants
22
. They do not 
code for proteins but interact with the host cell and use the host machinery 
for their replication
23
. The hepatitis delta virus of humans has an RNA 
genome similar to viroids but has protein coat derived from hepatitis B 
virus (HBV) and cannot produce one of its own. It is therefore a defective 
virus and cannot replicate without the help of HBV
24
. Similarly, the 
virophage 'sputnik' is dependent on mimivirus, which infects the protozoan 
Acanthamoeba castellanii
25
. These viruses that are dependent on the 
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presence of other virus species in the host cell are called satellites and may 
represent evolutionary intermediates of viroids and viruses. 
Computer analysis of viral and host DNA sequences is giving a better 
understanding of the evolutionary relationships between different viruses and 
may help identify the ancestors of modern viruses. To date, such analyses have 
not helped to decide on which of these hypotheses are correct. However, it 
seems unlikely that all currently known viruses have a common ancestor and 






Viruses display a wide diversity of shapes and sizes, called morphologies. 
Generally viruses are much smaller than bacteria. Most viruses that have been 
studied have a diameter between 10 and 300 nanometres. Some filoviruses 
have a total length of up to 1400 nm; their diameters are only about 80 nm
26
. 
Most viruses cannot be seen with a light microscope so scanning and 
transmission electron microscopes are used to visualise virions.
[59]
 To increase 
the contrast between viruses and the background, electron-dense "stains" are 
used.  
A complete virus particle, known as a virion, consists of nucleic acid 
surrounded by a protective coat of protein called a capsid. These are formed 
from identical protein subunits called capsomers.
 
Viruses can have a lipid 
"envelope" derived from the host cell membrane. The capsid is made from 
proteins encoded by the viral genome and its shape serves as the basis for 
morphological distinction
27
. Virally coded protein subunits will self-assemble 
to form a capsid, generally requiring the presence of the virus genome. 
Complex viruses code for proteins that assist in the construction of their 
capsid. Proteins associated with nucleic acid are known as nucleoproteins, and 
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the association of viral capsid proteins with viral nucleic acid is called a 
nucleocapsid (Fig. 1.3).  
 
 
Figure 1.3:  Virion structure. 
 
The capsid and entire virus structure can be mechanically (physically) probed 
through atomic force microscopy
28-30
.  
In general, there are four main morphological virus types: 
Helical: These viruses are composed of a single type of protomer stacked 
around a central axis to form a helical structure, which may have a central 
cavity, or hollow tube (Fig. 1.4). This arrangement results in rod-shaped or 
filamentous virions: these can be short and highly rigid, or long and very 
flexible. Long helical particles must be flexible in order to prevent forces 
snapping the structure. The genetic material, generally single-stranded RNA, 
but ssDNA in some cases, is housed on the inside of the tube, protected from 
the outside, through a bond into the protein helix by interactions between the 
negatively charged nucleic acid and positive charges on the protein. Overall, 
the length of a helical capsid is related to the length of the nucleic acid 
contained within it and the diameter is dependent on the size and arrangement 
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Figure 1.4:  Diagram of a helical capsid. 
 
Icosahedral: Cubic (=Icosahedral) capsid symmetry results in a spherical 
appearance of viruses at low magnification but actually consists of capsomers 
arranged in a regular geometrical pattern, similar to a soccer ball, hence they 
are not truly ―spherical‖. Capsomers are ring shaped structures constructed 
from five to six copies of protomers. These associate via non-covalent bonding 
to enclose the viral nucleic acid, though generally less intimately than helical 
capsids, and may involve one or more protomers. 
Most, if not all, of the polygonal viruses are icosahedral; like a geodesic dome, 
they are formed by equilateral triangles. Each triangle is composed of protein 
subunits (capsomeres), often in the form of hexons (multiples of six) that are 
the building blocks of the capsid. There are 12 vertices (the apical junctions of 
these triangles), each comprising a penton (five subunits). In order to construct 
a capsid from repeated subunits, a virus must 'know the rules' which dictate 
how these are arranged. For an icosahedron, the rules are based on the 




 An axis of two-fold rotational symmetry through the centre of each edge. 
 An axis of three-fold rotational symmetry through the centre of each face. 
 An axis of five-fold rotational symmetry through the centre of each corner. 
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Figure 1.5:  Icosahedral symmetry33. 
 
Envelope: Some species of virus envelop themselves in a modified form of 
one of the cell membranes, either the outer membrane surrounding an infected 
host cell, or internal membranes such as nuclear membrane or endoplasmic 
reticulum, thus gaining an outer lipid bilayer known as a viral envelope. This 
membrane is studded with proteins coded for by the viral genome and host 
genome; the lipid membrane itself and any carbohydrates present originate 
entirely from the host. The HIV and influenza virus use this strategy (Fig. 1.6). 
Most enveloped viruses are dependent on the envelope for their infectivity. 
 
 
Figure 1.6:  Examples of two enveloped viruses. (a) HIV has an icosahedral capsid 
which contains two positive-strand RNA copies and (b) Influenza A virus has an 
helical capsid which contains eight negative-strand RNA segments34. 
 
Complex: These viruses possess a capsid that is neither purely helical, nor 
purely icosahedral, and that may possess extra structures such as protein tails 
or a complex outer wall. Some bacteriophages, such as Enterobacteria phage 
T4 (Fig. 1.7) have a complex structure consisting of an icosahedral head 
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bound to a helical tail, which may have a hexagonal base plate with protruding 
protein tail fibres. This tail structure acts like a molecular syringe, attaching to 




Figure 1.7:  Structural overview of the T4 phage. 
 
The poxviruses are large, complex viruses that have an unusual morphology. 
The viral genome is associated with proteins within a central disk structure 
known as a nucleoid. The nucleoid is surrounded by a membrane and two 
lateral bodies of unknown function. The virus has an outer envelope with a 
thick layer of protein studded over its surface. The whole virion is slightly 
pleiomorphic, ranging from ovoid to brick shape
35
. Mimivirus is the largest 
known virus, with a capsid diameter of 400 nm. Protein filaments measuring 
100 nm project from the surface. The capsid appears hexagonal under an 
electron microscope, therefore the capsid is probably icosahedral. 
Some viruses that infect Archaea have complex structures that are unrelated to 
any other form of virus, with a wide variety of unusual shapes, ranging from 
spindle-shaped structures, to viruses that resemble hooked rods, teardrops or 
even bottles. Other archaeal viruses resemble the tailed bacteriophages, and 
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1.1.4 Genome 
An enormous variety of genomic structures can be seen among viral 
species; as a group they contain more structural genomic diversity (Table 1.1) 
than plants, animals, archaea, or bacteria. There are millions of different types 
of viruses; though only about 5,000 of them have been described in detail. A 
virus has either DNA or RNA genes and is called a DNA virus or a RNA virus  
respectively. The vast majority of viruses have RNA genomes. Plant viruses 










 Both DNA and RNA (at different stages in 














 Positive sense (+) 
 Negative sense (-) 
 Ambisense(+/-) 
Table 1.1:  Genomic diversity among viruses. 
 
Viral genomes are circular, as in the polyomaviruses, or linear, as in the 
adenoviruses. The type of nucleic acid is irrelevant to the shape of the 
genome. Among RNA viruses, the genome is often divided up into separate 
parts within the virion, in which case it is called segmented. Each segment 
often codes for one protein and they are usually found together in one capsid. 
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Every segment is not required to be in the same virion for the overall virus to 
be infectious, as demonstrated by the brome mosaic virus
27
.  
A viral genome, irrespective of nucleic acid type, is either single-stranded or 
double-stranded. Single-stranded genomes consist of an unpaired nucleic acid, 
analogous to one-half of a ladder split down the middle. Double-stranded 
genomes consist of two complementary paired nucleic acids, analogous to a 
ladder. Some viruses, such as those belonging to the Hepadnaviridae, contain 
a genome that is partially double-stranded and partially single-stranded. 
For viruses with RNA or single-stranded DNA, the strands are said to be ether 
positive-sense (called the plus-strand) or negative-sense (called the minus-
strand), depending on whether it is complementary to the viral messenger 
RNA (mRNA). Positive-sense viral RNA is identical to viral mRNA and thus 
can be immediately translated by the host cell. Negative-sense viral RNA is 
complementary to mRNA and thus must be converted to positive-sense RNA 
by an RNA polymerase before translation. DNA nomenclature is similar to 
RNA nomenclature, in that the coding strand for the viral mRNA is 
complementary to it (−), and the non-coding strand is a copy of it (+). 
Genome size varies greatly between species. The smallest viral genomes code 
for only four proteins and have a mass of about 10
6
 Daltons; the largest have a 
mass of about 10
8
 Daltons and code for over one hundred proteins
37
. RNA 
viruses generally have smaller genome sizes than DNA viruses because of a 
higher error-rate when replicating, and have a maximum upper size limit. 
Beyond this limit, errors in the genome when replicating render the virus 
useless or uncompetitive. To compensate for this, RNA viruses often have 
segmented genomes where the genome is split into smaller molecules, thus 
reducing the chance of error. In contrast, DNA viruses generally have larger 
genomes because of the high fidelity of their replication enzymes. 
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Viruses undergo genetic change by several mechanisms. These include a 
process called genetic drift where individual bases in the DNA or RNA mutate 
to other bases. Most of these point mutations are "silent", they do not change 
the protein that the gene encodes, but others can confer evolutionary 
advantages such as resistance to antiviral drugs. Antigenic shift occurs when 
there is a major change in the genome of the virus. This can be a result of 
recombination or reassortment.  
Viruses with segmented genomes, such as influenza virus, have another 
mechanism for generating diversity: reassortment
38-39
.  
When an influenza virus infects a cell, the individual RNA segments enter the 
nucleus. There they are copied many times to form RNA genomes for new 
infectious virions. The new RNA segments are exported to the cytoplasm, and 
then are incorporated into new virus particles which bud from the cell. If a cell 
is infected with two different influenza viruses, the RNAs of both viruses are 
copied in the nucleus.  
When new virus particles are assembled at the plasma membrane, each of the 
8 RNA segments may originate from either infecting virus.  
The progeny that inherit RNAs from both parents are called reassortants. One 
example of the evolutionary importance of reassortment is the exchange of 
RNA segments between mammalian and avian influenza viruses that give rise 
to pandemic influenza. For example, the 2009 H1N1 pandemic strain is a 
reassortant of avian, human, and swine influenza viruses (Fig. 1.8). 
Chapter 1                                                                                                    Introduction 
- 14 - 
 
 
Figure 1.8:  History of Reassortment Events in the Evolution of the 2009 Influenza A 
(H1N1) Virus. 
 
Reassortment can only occur between influenza viruses of the same type. Why 
influenza A viruses never exchange RNA segments with influenza B or C 
viruses is not understood. However, the reason is probably linked to the 
packaging mechanism that ensures that each influenza virion contains at least 
one copy of each RNA segment
38-40
. 
Genetic recombination is the process by which a strand of DNA is broken and 
then joined to the end of a different DNA molecule. This can occur when 
viruses infect cells simultaneously and studies of viral evolution have shown 
that recombination has been rampant in the species studied. Recombination is 




1.1.5 Replication cycle 
Viral populations do not grow through cell division, because they are 
acellular. Instead, they use the machinery and metabolism of a host cell to 
produce multiple copies of themselves, and they assemble in the cell. 
Chapter 1                                                                                                    Introduction 
- 15 - 
 
The life cycle of viruses (Fig. 1.9) differs greatly between species but there are 
six basic stages in the life cycle of viruses: 
 
Figure 1.9:  Life cycle of viruses. 
 
1. Attachment is a specific binding between viral capsid proteins and specific 
receptors on the host cellular surface. This specificity determines the host 
range of a virus. For example, HIV infects only human T cells, because its 
surface protein, gp120, can interact with CD4 and chemokine receptors on 
the T cell's surface. This mechanism has evolved to favour those viruses 
that only infect cells in which they are capable of replication. Attachment 
to the receptor can induce the viral-envelope protein to undergo changes 
that results in the fusion of viral and cellular membranes. 
 
2. Penetration follows attachment; viruses enter the host cell through 
receptor mediated membrane fusion or endocytosis (Fig. 1.10A). This is 
often called viral entry. In the case of fusion the viral membrane fuses with 
the cell membrane and the protein capsid is released. Once in the 
cytoplasm the protein capsid is removed and the viral genome is freed. 
Depending on the nature of the virus the viral genome may stay in the 
cytoplasm or it may enter the nucleus before beginning the next stage of 
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the life cycle. In the case of engulfment, o endocytosis, the initial 
adsorption process is the same, but rather than directly fusing with the cell 
membrane, the cell is stimulated to take-up or engulf the entire eukaryotic 
virus. Once inside the cytoplasm the enveloped eukaryotic virus is said to 
be in a vescicle. Subsequently, the two lipid membranes of the vesicle 
fuse, releasing the capsid covered virus. The capsid is then removed and 
the viral genome is freed for the next stage of viral replication
4,7
. Some of 
the non-enveloped viruses like picornaviruses and phages are capable of 
directly injecting their genome into the host cell (Fig. 1.10B). The 
infection of plant cells is different from that of animal cells. Plants have a 
rigid cell wall made of cellulose, so most viruses can only get inside the 
cells after trauma to the cell wall. However, viruses such as tobacco 





      Figure 1.10:  A. Mechanisms of viral penetration: fusion and endocytosis; B.     
      Genome injection in the host cell by phage. 
 
3. Uncoating is a process in which the viral capsid is degraded by viral 
enzymes or host enzymes thus releasing the viral genomic nucleic acid. A 
key step in uncoating is the acidification of the content of the endosome to 
a pH of about 5, owing to the activity of a proton pump present in the 
membrane. The low pH causes rearrangement of coat components, which 
then expose normally hidden hydrophobic sites. They bind to the lipid 
bilayer of the membrane, causing the extrusion of the viral core into the 
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cytosol. For influenza virus, the acid-sensitive component is the core HA2 
unit of the haemagglutinin, for adenoviruses, it is the penton base. There 
are four virus uncoating strategies: some enveloped viruses, such as HIV, 
fuse directly with the host cell plasma membrane to release their capsid 
(green) into the cytosol (Fig. 1.11A). Other enveloped viruses, such as 
influenza virus, first bind to cell-surface receptors, triggering receptor-
mediated endocytosis. When the endosome acidifies, the virus envelope 
fuses with the endosomal membrane, releasing the nucleocapsid (blue) into 
the cytosol (Fig. 1.11B). Poliovirus, a nonenveloped virus, binds to a 
receptor (green) on the host cell surface and then forms a pore in the host 
cell membrane to extrude its RNA genome (blue) (Fig. 1.11C). 
Adenovirus, another nonenveloped virus, uses a more complicated 
strategy. It induces receptor-mediated endocytosis and then disrupts the 
endosomal membrane, releasing part of the capsid into the cytosol. The 
capsid eventually docks onto a nuclear pore and releases its DNA genome 





Figure 1.11:  Uncoating strategies. 
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4 Replication involves synthesis of viral messenger RNA (mRNA) for 
viruses except positive sense RNA viruses, viral protein synthesis and 
assembly of viral proteins and viral genome replication. 
 
5 Assembly of the virus particles, in which post-translational modification of 
the viral proteins often occurs. In viruses such as HIV, this modification 
(sometimes called maturation) occurs after the virus has been released 
from the host cell. 
 
6 Viruses are released from the host cell by lysis (a process that kills the cell 
by bursting its membrane) or budding (a process that involves taking a 
portion of the cell membrane) (Fig. 1.12A). Enveloped viruses (e.g., HIV) 
typically are released from the host cell by budding. During this process 
the virus acquires its envelope, which is a modified piece of the host's 
plasma membrane. Some viruses undergo a lysogenic cycle (Fig. 1.12B) 
where the viral genome is incorporated by genetic recombination into a 
specific place in the host's chromosome. The viral genome is then known 
as a "provirus" or, in the case of bacteriophages a "prophage". Whenever 
the host divides, the viral genome is also replicated. The viral genome is 
mostly silent within the host; however, at some point, the provirus or 





Figure 1.12:  Release strategies: A. Budding; B. Lysis or lysogenesis. 
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The genetic material within viruses, and the method by which the material is 
replicated, vary between different types of viruses: 
 DNA viruses: The genome replication of most DNA viruses takes place in 
the cell's nucleus. If the cell has the appropriate receptor on its surface, 
these viruses enter the cell by fusion with the cell membrane or by 
endocytosis. Most DNA viruses are entirely dependent on the host cell's 
DNA and RNA synthesising machinery, and RNA processing machinery. 





 RNA viruses: Replication usually takes place in the cytoplasm. RNA 
viruses can be placed into about four different groups depending on their 
modes of replication. The polarity (whether or not it can be used directly to 
make proteins) of the RNA largely determines the replicative mechanism, 
and whether the genetic material is single-stranded or double-stranded. 
RNA viruses use their own RNA replicase enzymes to create copies of 
their genomes.  
 
 Reverse transcribing viruses: These replicate using reverse transcription, 
which is the formation of DNA from an RNA template. Reverse 
transcribing viruses containing RNA genomes use a DNA intermediate to 
replicate, whereas those containing DNA genomes use an RNA 
intermediate during genome replication. Both types use the reverse 
transcriptase enzyme to carry out the nucleic acid conversion. Retroviruses 
often integrate the DNA produced by reverse transcription into the host 
genome. They are susceptible to antiviral drugs that inhibit the reverse 
transcriptase enzyme, e.g. zidovudine and lamivudine. An example of the 
first type is HIV, which is a retrovirus. Examples of the second type are 
the Hepadnaviridae, which includes Hepatitis B virus
46
. 
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1.1.6 Classification 
Classification seeks to describe the diversity of viruses by naming and 
grouping them on the basis of similarities. In 1962, André Lwoff, Robert 
Horne, and Paul Tournier were the first to develop a means of virus 
classification, based on the Linnaean hierarchical system. This system bases 
classification on phylum, class, order, family, genus, and species. Viruses 
were grouped according to their shared properties (not those of their hosts) and 
the type of nucleic acid forming their genomes. Viruses are mainly classified 
by phenotypic characteristics, such as morphology, nucleic acid type, mode of 
replication, host organisms, and the type of disease they cause
47-48
.  
Currently there are two main schemes used for the classification of viruses: the 
ICTV system and Baltimore classification system. Accompanying this broad 
method of classification are specific naming conventions and further 
classification guidelines set out by the International Committee on Taxonomy 
of Viruses. 
 
a. ICTV classification 
The International Committee on Taxonomy of Viruses (ICTV) developed 
the current classification system and wrote guidelines that put a greater weight 
on certain virus properties to maintain family uniformity. A unified taxonomy 
(a universal system for classifying viruses) has been established. The 7th lCTV 
Report formalised for the first time the concept of the virus species as the 
lowest taxon (group) in a branching hierarchy of viral taxa
49
. However, at 
present only a small part of the total diversity of viruses has been studied, with 
analyses of samples from humans finding that about 20% of the virus 
sequences recovered have not been seen before, and samples from the 
environment, such as from seawater and ocean sediments, finding that the 
large majority of sequences are completely novel. 
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The general taxonomic structure is as follows: 
Order (-virales)  
         Family (-viridae)  
            Subfamily (-virinae)  
               Genus (-virus)  
                   Species (-virus) 
So far, six orders have been established by the ICTV: the Caudovirales, 
Herpesvirales, Mononegavirales, Nidovirales, Picornavirales, and 
Tymovirales. Most notably, species names generally take the form of virus. 
The establishment of an order is based on the inference that the virus families 
contained within a single order have most likely evolved from a common 
ancestor. The majority of virus families remain unplaced. Currently (2009) 6 





b. Baltimore classification 
The Baltimore classification of viruses is based on the method of viral 
mRNA synthesis. The Nobel Prize-winning biologist David Baltimore devised 
the Baltimore classification system. The ICTV classification system is used in 
conjunction with the Baltimore classification system in modern virus 
classification.  
Baltimore classification is a classification system that places viruses into one 
of seven groups depending on a combination of their nucleic acid (DNA or 
RNA), strandedness (single-stranded (ss) or double-stranded (ds)), Sense, and 
method of replication (may or may not use reverse transcriptase, RT). 
Additionally, ssRNA viruses may be either sense (+) or antisense (−). These 
groups are designated by Roman numerals and discriminate viruses depending 
on their mode of replication, and genome type.  
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The replication strategy of the virus depends on the nature of its genome. 





Figure 1.13:  Baltimore classification. 
 
Viruses belonging to group I and II are DNA viruses (Table 1.2). 
 
 Group I: Double-stranded DNA (dsDNA)  
(Adenoviruses; Herpesviruses; Poxviruses; etc).  
Viruses having a dsDNA genome that make mRNA by asymmetric 
transcription. Some replicate in the nucleus e.g adenoviruses using cellular 
proteins. Poxviruses replicate in the cytoplasm and make their own enzymes 
for nucleic acid replication. 
 
 Group II: Single-stranded (+)sense DNA (ssDNA)  
(Parvoviruses; circoviruses) 
Replication occurs in the nucleus, involving the formation of a (-)sense strand, 
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1.Adenoviridae Adenovirus Naked Icosahedral Ds I 
2.Papillomavirus Papillomavirus Naked Icosahedral ds circular I 
3.Parvoviridae Parvovirus B19 Naked Icosahedral Ss II 
4.Herpesviridae HSV, VZV, cytomegalovirus, EBV Enveloped Icosahedral Ds I 
5.Poxviridae Smallpox virus, vaccinia virus  Complex coats Complex ds I 
6.Hepadnaviridae Hepatitis B virus Enveloped Icosahedral Circular, 
partially ds 
VII 
7.Polyomaviridae Polyoma virus, JC virus Naked Icosahedral ds circular I 
8.Circoviridae Transfusion transmitted virus Naked Icosahedral Ss circular II 
Table 1.2:  DNA viruses. 
 
Viruses belonging to group III, IV and V are RNA viruses (Table 1.3). 
 
 Group III: Double-stranded RNA (dsRNA)  
(Reoviruses; Birnaviruses) 
Viruses having a dsRNA genome that make mRNA by asymmetric 
transcription (Fig. 1.14A). Most have multiple pieces of dsRNA, each of 
which apparently contains the information for the synthesis of a single protein. 
 
 Group IV: Single-stranded (+)sense RNA ((+)ssRNA)  
(Picornaviruses; Togaviruses; Flaviviruses; Coronaviruses; etc) 
Viruses having an ssRNA genome that make mRNA of base sequence 
identical to the genomic RNA. Infect, small amounts of (–)RNA are produced 
and used as templates to greatly amplify viral (+)RNA, which is encapsidated 
into new progeny virions (Fig. 1.14B). 
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Figure 1.14:  Distinct life cycle of dsRNA (A), (+)RNA viruses(B). 
 
 Group V: Single-stranded (-)sense RNA ((−)ssRNA) 
(Orthomyxoviruses; Rhabdoviruses; etc)  
Viruses having an ssRNA genome that make mRNA with a base sequence 
complementary to the genomic RNA. Must have a virion particle RNA 
directed RNA polymerase. 
 









1.Reoviridae Reovirus, Rotavirus Naked Icosahedral ds III 
2.Picornaviridae Enterovirus, Rhinovirus, Hepatovirus, 
Cardiovirus, Poliovirus, Coxsackie  
Naked Icosahedral ss IV 
3.Calciviridae Norwalk virus, HEV Naked Icosahedral        ss IV 
4.Togaviridae Rbubella virus Enveloped Icosahedral        ss IV 
5.Arenaviridae Lymphocytic choriomeningitis virus Enveloped Complex ss(-) V 
6.Flaviviridae Dengue virus, HCV, Yellow fever virus Enveloped Icosahedral        ss IV 
7.Orthomyxoviridae Influenza A, B and C viruses, Isavirus Enveloped Helical ss(-) V 
8.Paramyxoviridae Measles virus, Mumps virus, RSV Enveloped Helical ss(-) V 
9.Bunyaviridae California encephalitis virus, Hantavirus Enveloped Helical ss(-) V 
10.Rhabdoviridae Rabies virus Enveloped Helical ss(-) V 
11.Filoviridae Ebola virus, Marburg virus Enveloped Helical ss(-) V 
12.Coronaviridae Corona virus Enveloped Helical        ss IV 
13.Astroviridae Astrovirus Naked Icosahedral        ss IV 
14.Bornaviridae Borna disease virus Enveloped Helical ss(-) V 
Table 1.3:  RNA viruses. 
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Viruses belonging to group VII are DNA viruses (Table 1.2). 
 
 VI: Single-stranded (+)sense RNA with DNA intermediate in life-
cycle  (ssRNA-RT ) (Retroviruses) 
Genome is (+)sense but unique among viruses in that it is diploid, and does not 
serve as mRNA, but as a template for reverse transcription. After cDNA 
synthesis by reverse transcription, proviral cDNA is integrated into the host 
chromosome and transcribed to produce (+)RNA (Fig. 1.15) that is translated 
(1) and then packaged (2) into new virions that are released by budding. HIV is 
a member of this group. 
 
Figure 1.15:  Life cycle of retrovirus. 
 
 VII: Double-stranded DNA with RNA intermediate (dsDNA-RT) 
(Hepadnaviruses) 
This group of viruses also relies on reverse transcription, but unlike the 
Retroviruses, this occurs inside the virus particle on maturation. 
Hepadnaviruses replicate through an RNA intermediate which they transcribe 
back into cDNA using reverse transcriptase. The hepatitis B virus can be 
found in this group. 
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As an example of viral classification, the chicken pox virus, varicella zoster 
(VZV), belongs to the order Herpesvirales, family Herpesviridae, subfamily 
Alphaherpesvirinae, and genus Varicellovirus. VZV is in Group I of the 





1.2 Viruses and human disease 
 
Viruses are of intense interest because many cause serious illness in human 
or domestic animals and others damage crop plants. During the last century, 
progress in the control of infectious diseases through improved sanitation, 
safer water supplies, the development of antibiotics and vaccines, and better 
medical care have dramatically reduced the threat to human health from these 
agents, especially in developed countries. The first step in treating viral 
infection is preventing its occurrence and spread. The use of vaccines has led 
to effective control of the most dangerous of the viruses. Smallpox virus has 
been eradicated worldwide by means of an ambitious and concerted effort, 
sponsored by the World Health Organization, to vaccinate all people at risk for 
the disease. Poliovirus and measles virus have been eliminated from the 
Americas by intensive vaccination programs. There is hope that these two 
viruses will also be eradicated worldwide in the near future. Vaccines exist for 
the control of many other viral diseases including, among others, mumps, 
rabies, rubella, chickenpox, shingles, influenza, hepatitis B, hepatitis A, yellow 
fever, Japanese encephalitis, rotaviral gastroenteritis and, very recently, 
papillomaviral disease that is the primary cause of cervical cancer. The 
dramatic decline in the death rate from infectious disease has led to a certain 
amount of complacency. However, viral diseases continue to plague humans, 




Chapter 1                                                                                                    Introduction 
- 27 - 
 
There are thousands of viruses, and in humans they cause a wide range of 
diseases (Fig. 1.16).  
 
 
Figure 1.16:  Simplified classification scheme of the main viruses commonly  
             associated with human diseases53.  
 
For instance, rhinoviruses (Group: IV-(+)ssRNA, family: Picornaviridae, 
genus: enterovirus, species: Human rhinovirus A,B,C) cause colds; influenza 
viruses (Group: V-(-)ssRNA, family: Orthomyxoviridae, genus: Influenza 
virus A,B,C) cause flu; adenoviruses (HAdV, Group: I-dsDNA, family: 
Adenoviridae, species: Human adenovirus A to G) cause various respiratory 
problems (mainly species HAdV-B and C), conjunctivitis (HAdV-B and D) and 
gastroenteritis (HAdV-F serotypes 40 and 41); rotaviruses (Group: III-dsRNA 
Family: Reoviridae, genus: Rotavirus, species: Rotavirus A-E) cause 
gastroenteritis. Poliovirus (Group: IV-(+)ssRNA, family: Picornaviridae, 
genus: enterovirus, species: human enterovirus C) can make their way to the 
spinal cord and cause paralysis, while coxsackieviruses (Group: IV-(+)ssRNA, 
family: Picornaviridae, genus: enterovirus, species: Human enterovirus A,B) 
and echoviruses (Group: IV-(+)ssRNA, family: Picornaviridae, genus: 
enterovirus, species: Human enterovirus B) sometimes infect the heart or the 
membranes surrounding the spinal cord or lungs
52
.  
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Although viruses cause disruption of healthy homeostasis, resulting in disease, 
they may exist relatively harmlessly within an organism. An example would 
include the ability of the herpes simplex virus, which causes cold sores, to 
remain in a dormant state within the human body. This is called latency
54
 and 
is a characteristic of the herpesviruses. Herpesviruses belong to a large virus 
family, Herpesviridae (Group: I-dsDNA) and there are eight distinct viruses in 








pathophysiology Site of latency 
HHV1 Herpes simplex virus-1 (HSV-1) Α Mucoepithelial     Oral and genital herpes Neuron 
HHV2 Herpes simplex virus-2 (HSV-2) Α Mucoepithelial       Oral and genital herpes      Neuron 
HHV3 Varicella Zoster virus (VZV) Α Mucoepithelial           Chickenpox and shingles      Neuron 
HHV4 Epstein-Barr virus (EBV), 
lymphocryptovirus 
Γ B cells and  
epithelial cells 
      Infectious mononucleosis, 
lymphoma, leukoplakia 
          B cell 
HHV5 Cytomegalovirus (CMV) Β Monocyte, 
lymphocyte and 
epithelial cells 
   Infectious mononucleosis,    
retinitis 
   Monocyte 
  Lymphocyte 
HHV6 Roseolovirus, Herpes 
lymphotropic virus 
Β T cells Sixth disease T cells 
HHV7 Roseolovirus Β T cells Sixth disease T cells 
HHV8 Kaposi‘s sarcoma-associated 
herpesvirus (KSHSV), a type 
of rhadinovirus 





Table 1.4:  Human Herpesvirus (HHV) classification. 
 
For example Herpes simplex viruses (HSV-1,2) cause cold sores and genital 
herpes (a sexually transmitted disease); the Epstein-Barr virus (EBV) and the 
cytomegalovirus (CMV) cause infectious mononucleosis and the varicella 
zoster (VZV) virus causes shingles and chickenpox.  
Most people have been infected with at least one of these types of herpes 
virus
56
. However, these latent viruses might sometimes be beneficial, as the 
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Other viruses cause a variety of conditions from measles and mumps to 
hepatitis and AIDS. Viral infections primarily affect respiratory and 
gastrointestinal system; epithelium, mucous membranes and endothelium of 
skin, mouth and genitals; lymphoid tissue, liver and other organs and central 





Figure 1.17:  Main types of viral infection and the most notable species 
involved. 
 
1.2.1 Infection of oropharynx and 
respiratory tract 
Oropharynx and respiratory tract are the most common sites of infection. 
Viruses spread through droplets and aerosols, food, water and saliva; through 
close contact and hands. Similar respiratory symptoms may be caused by 
many viruses; in contrast, a single virus can cause different symptoms in 
different people. For example, in some individuals the virus can cause mild 
upper respiratory infection, in others life-threatening pneumonia.  
Symptoms and severity of a viral respiratory illness depend on: virus nature, 
site of infection (upper or lower respiratory tract), immune status and age of 
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individual. Pharyngitis and other oropharynx diseases are common 
manifestations of viral infection. For example, symptoms such as acute 
pharyngitis, fever and oral vesicular lesions are characteristic of coxsackie A 
virus (herpangina, hand-foot and mouth disease) and coxsackie B virus and 
echovirus. Herpesviruses cause local primary infection on oral mucous 
membrane and face. Latent infection in neurons is followed by a 
gingivostomatitis caused by herpes virus and occurs in the form of herpes 
labialis. Epstein-Barr virus (EBV) and human herpes virus 6 (HHV6) can 
cause pharyngitis. Rhinovirus and coronavirus are the predominant cause of 
the common cold, upper respiratory tract infection.  
Both pharingitis and colds can be caused by specific serotypes of echovirus 
and coxsackievirus, adenovirus, influenza virus, parainfluenza virus and 
respiratory syncytial virus. Respiratory tract‘s infections may also degenerate 
into more serious illnesses. Symptoms of these infections are bronchitis 
(inflammation of bronchioles), pneumonia and related conditionats. 
Parainfluenza virus and respiratory syncytial virus create more damage to 
infants and young children, but only cause asymptomatic infections or 
symptoms of the common cold in adults.  
Influenza virus is probably the best known and most feared virus among the 
common respiratory viruses, because annually you can check the spread of 
new strains of viruses. The viral agents that cause pneumonia include 
adenovirus, paramyxovirus and varicella-zoster virus primary infections.  
 
1.2.2 Gastrointestinal infections 
Gastrointestinal infections can cause gastroenteritis, diarrhea, or be 
asymptomatic. Norovirus (Norwalk virus), adenovirus, astrovirus, rotavirus, 
coronavirus infect small intestine but not colon, causing damage to the 
epithelial lining and the intestinal villi and resulting in malabsorption of water 
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and electrolyte imbalance. Rotavirus and adenovirus 40-41 are the leading 
cause of infantile gastroenteritis.  
1.2.3 Skin infections 
Skin viral diseases may be the effect of infections of the mucous membrane 
or small cuts or skin abrasions (HSV), as in the case of a secondary infection 
after the onset of viremia (VZV or smallpox) or be the result of an 
inflammatory response against viral agents (measles rash). The classic 
childhood exanthems, accompanied by fever, include exanthema subitum 
(HHV6), erythema infectiosum (parvovirus B19) and in unvaccinated children 
varicella, measles and rubella. Yellow fever virus (YFV), dengue virus and 
other viruses, causing hemorrhagic fevers, infect epithelial cells lining the 
blood vessels and can affect the structure. This produces a hemorrhagic rash 
with petechiae and ecchymoses. 
 
1.2.4 Eye infections 
Conjunctivitis (pink eye) is a typical feature of many childhood infections, 
and is caused by specific serotypes of adenovirus (3, 4a and 7), measles virus 
and rubella virus. Keratoconjunctivitis, caused by adenovirus (8, 19a and 
37), HSV o VZV, affects the cornea and can cause serious damage. Enterovirus 
70 and coxsackie virus A24 can cause acute hemorrhagic conjunctivitis. 
Chorioretinitis is associated with congenital and in immunocompromised 
persons CMV infection. 
 
1.2.5 Organs and tessues infection 
Main organs infection can cause significant disease or determine 
subsequent virus spreading. Symptoms can be the effect of tissues damage or 
of inflammatory responses. The liver is a major target of many viruses. For 
example, the hepatitis symptoms may be caused by hepatitis viruses A, B, C, 
D and E and yellow fever virus and these are often associated with infectious 
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mononucleosis by EBV and CMV infections. The liver is also the biggest target 
in disseminated HSV infections in infants and children. The heart and other 
muscles are susceptible to viral infections and the resulting damage. 
Coxsackievirus can cause myocarditis or pericarditis in infants, children and 
adults. The coxsackie B virus can infect and cause the muscles pleurodynia 
(Bornholm disease). Other viruses (eg influenza virus and CMV) can infect the 
heart. Infection of the secretory glands, accessory sex organs and mammary 
glands causes a contagious spread of the virus (CMV, mumps virus). For 
example, mumps and epidemic parotitis is a viral disease of the human 
species, caused by the mumps virus, whose most typical onset is the painful 
swelling of the salivary glands (classically the parotid gland). Kidney CMV 
infection and reactivation cause problems in immunocompromised people and 
are a major cause of failure of kidney transplantation. 
 
1.2.6 Central Nervous System (CNS) infections 
Viral infections of the brain and CNS can cause the most serious viral 
diseases due to CNS importance and to its very limited capacity to repair 
damage. A virus can spread to the CNS from the blood (arbovirus) or 
macrophages (acquired human immunodeficiency virus HIV); from peripheral 
neurons infection, or it may first infect the skin (HSV) or a muscle (rabies 
virus) and then progress to the neurons that innervate the infected area. Virus 
then infects neurons that express a viral receptor. For example, the temporal 
lobe is a target in the encephalitis by HSV, the horn of Ammon in rabies, 
anterior horn of the spinal cord and motor neurons in paralytic poliomyelitis 
(Enteroviruses). Aseptic meningitis is caused by inflammation and swelling 
of the meninges that involve the brain and the spinal cord in response to 
infection by enteroviruses (particularly coxsackievirus and echovirus), HSV-2, 
mumps virus or lymphocytic choriomeningitis virus (LCM virus). The disease 
is usually self-limiting and, unlike bacterial meningitis, resolves without 
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sequelae unless the virus does not access and infect neurons or brain 
(meningoencephalitis). 
Encephalitis and myelitis are fatal or cause significant damage and permanent 
neurological sequelae. HSV, VZV, rabies virus, California encephalitis virus,  
St. Louis encephalitis virus (SLEV) and measles virus are potential causes of 
encephalitis. Many polioviruses and other enteroviruses cause a paralytic 
disease (myelitis). HSV and VZV are ubiquitous and usually cause 
asymptomatic latent infections of the CNS, but can also cause encephalitis. 
Other neurological syndromes caused by viruses include HIV dementia, 
Tropical spastic paraparesis or human T-lymphotropic virus type I (HTLV-
I)-associated myelopathy, progressive multifocal leukoencephalopathy 
caused by the papovavirus JC in immunocompromised people, and 
spongiform encephalopathy (kuru, Creutzfeldt-Jakob syndrome, Gerstmann-
Straussler-Scheinker syndrome) that are believed to be caused by prions. 
 
1.2.7 Sexually transmitted diseases 
Although sexual transmission is not a very effective way to virus spread, it 
is the major spread route of HPV, HSV, CMV, HIV, HTLV-1, HBV, hepatitis C 
virus (HCV) and hepatitis D (HDV). Papillomavirus and HSV-2 establish local 
primary infection causing recurrent disease at the same site. CMV and HIV 
enter the bloodstream and infect lymphoid cells, while HBV and HCV are 
transported to the liver. These viruses are present in blood, semen and vaginal 
secretions, through which virus can be transmitted to sexual partners and 
infants (neonatal or perinatal transmission). 
 
1.2.8 Syndromes with a possible viral etiology 
Many diseases cause symptoms or have the epidemiological features or 
other similar to those of viral infections, or may be the sequelae of viral 
infections (eg, inflammatory responses to persistent viral infection). These 
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1.2.9 Chronic and potentially oncogenic infections 
Some viruses can cause life-long or chronic infections, where the viruses 
continue to replicate in the body despite the host's defence mechanisms
59
. 
Chronic infections are established when the immune system has difficulty in 
resolving the infection. People chronically infected are known as carriers, as 
they serve as reservoirs of infectious virus
60
. In populations with a high 
proportion of carriers, the disease is said to be endemic
61
. In contrast to acute 
lytic viral infections this persistence implies compatible interactions with the 
host organism. Persistent viruses may even broaden the evolutionary potential 
of host species. CMV and other herpesviruses, hepatitis B, C and D viruses 
and retroviruses cause chronic productive infections. HBV, HCV, EBV, 
papilloma virus, and HTLV-1 are associated with human tumors.  
Cofactors, chromosomal aberrations, or both, convert a clone of cells, 
containing a virus, in cancer. EBV usually causes infectious mononucleosis, 
but is also associated with African Burkitt's lymphoma and nasopharyngeal 
carcinoma, HTLV-1 is associated with adult human T cell leukemia. Many 
papillomaviruses (HPV) cause a simple hyperplasia, characterized by the 
development of warts; however, many other strains of HPV have been linked 
to cancer in humans (eg, types 16 and 18 are associated with cervical cancer). 
Chronic infection with HBV and HCV has been associated with 
hepatocellular carcinoma. HSV-2 has been associated with human cervical 




1.3 Antiviral strategies 
 
Effective vaccines have led, or might lead, to the eradication of important 
viral pathogens, such as smallpox, polio, measles, mumps and rubella. But 
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other viral diseases, particularly human immunodeficiency virus (HIV) and 
hepatitis C virus (HCV), have so far proved to be intractable to the vaccine 
approach. The need for effective antiviral drugs is further emphasized by the 
lack of vaccines for most respiratory-tract virus infections (adenovirus, 
rhinovirus, parainfluenza virus and respiratory syncytial virus (RSV)), the 
widely occurring human papilloma viruses (HPV) and herpesviruses (herpes 
simplex virus types 1 and 2 (HSV-1,-2), varicellazoster virus (VZV), Epstein–
Barr virus (EBV), cytomegalovirus (CMV), human herpesviruses types 6, 7 
and 8 (HHV-6, -7, -8)), and the vast array of haemorrhagic fever viruses. And 
although vaccines have been developed for hepatitis B virus (HBV) and 
influenza virus types A and B, their use has not eliminated the need for 
effective chemotherapeutic agents. Many new antiviral drugs have been 
licensed in recent years, most of which are used for the treatment of HIV 
infections; of the current repertoire of more than 30 drugs, 16 are anti-HIV, 5 
are anti-CMV, 5 are anti-HSV and anti-VZV, 1 is anti-RSV, 3 are anti-hepatitis 
and 4 are anti-influenza. But there is considerable room for improvement, as 
these compounds are not always efficacious or well tolerated. 
The emergence of viral resistance to drugs and drug-related side effects are 
among the main reasons for further refinement of antiviral drug design and 
development
62
. The basic strategies that are used to design antiviral drugs 




3 Viral components synthesis (through the inhibition of 
viral enzymes); 
4 Assembly; 
5 Release phase. 
 
Chapter 1                                                                                                    Introduction 
- 36 - 
 
 
Figure 1.18:  Antiviral strategies63. 
 
1.3.1 Entry inhibitors 
One anti-viral strategy is to interfere with the ability of a virus to infiltrate a 
target cell. The virus must go through a sequence of steps to do this, beginning 
with binding to a specific "receptor" molecule on the surface of the host cell 
and ending with the virus "uncoating" inside the cell and releasing its contents. 
Viruses that have a lipid envelope must also fuse their envelope with the target 
cell, or with a vesicle that transports them into the cell, before they can uncoat. 
The entry stage of viral replication cycle can be inhibited in two ways: 
1. Using agents which act on viral-enveloped proteins. This includes 
antibodies and synthetic ligands. 
2. Using agents which bind to the host cell receptors. This may include 
natural ligands of the receptor and anti-receptor antibodies. 
 
 Agents which act on viral-enveloped proteins 
Enveloped proteins or glycoproteins contain oligosaccharide chains 
(glycans) covalently attached to polypeptide side-chains. Glycoproteins are 
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often important integral membrane proteins, where they play a role in cell-cell 
interactions. The N-glycosylation of viral enveloped protein is required for the 
folding, assembly and infectivity of several viruses.  
Belong to this class: 
1. Polyanionic compounds: For example, polysulphates (such as 
polyvinylalcohol sulphate, Fig. 1.19A), polysulphonates (such as 
polyvinylsulphonate, Fig. 1.19B), polycarboxylates, polynucleotides (such 
as zintevir, polyoxometalates and negatively charged albumins) have been 
shown to inhibit HIV replication by preventing virus attachment 
(adsorption) to the surface of the host cell. All of these negatively charged 
polymers might be expected to interact with the positively charged amino 
acids in the V3 loop of the HIV glycoprotein, gp120, which is rich in 
arginine (R) and lysine (K) residues. In doing so, the polyanions shield the 
V3 loop and therefore hamper the binding of the HIV virions to heparin 
sulphate, the primary binding site at the cell surface, before more specific 
binding occurs with the CD4 receptor on CD4+ cells. Heparan sulphate is 
widely expressed on animal cells, and is involved in virus–cell binding for 
a broad array of enveloped viruses, including HSV and dengue virus. 
Moreover, these polyanions are not only active against HIV, but also 
against HSV and other sexually transmitted disease (STD) pathogens, such 





Figure 1.19:  Viral adsorption inhibitors: polyvinylalcohol sulphate (A) and  
      polyvinylsulphonate (B). 
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2. Glycans inhibitors: Glycans on the viral envelope often have a crucial 
role in enabling an efficient transmission of the pathogen and/or entry 
into its susceptible target cells. Some agents interfere with the 
glycosylation enzymes from the cell, others act by directly binding to 
the intact glycans on the viral envelope. For example, MBI-3253 or 
Celgosivir (Fig. 1.20A) is an alpha-glucosidase I inhibitor with a 
potent antiviral activity in vitro and in vivo against several viruses, 
including HIV-1, herpes simplex virus (HSV), bovine viral diarrhea 
virus (BVDV) and HCV. It is currently undergoing phase II 
development for the treatment of HCV infection.  Among agents that 
interact with the viral-envelope glycans there are carbohydrate- 
binding agents (CBAs)(Fig. 1.20B). These compounds have a dual 
mechanism of antiviral action: first, through direct antiviral activity, by 
binding to the glycans of the viral envelope and subsequently blocking 
virus entry, and second, through indirect (additional) antiviral action 
resulting from the progressive creation of deletions in the envelope 
glycan shield, thereby triggering the immune system to act against 







Figure 1.20:  Glycans inhibitors: A. Celgosivir; B. CBAs. 
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 Agents which bind to the host cell receptors 
It is about agents against receptors on the host cell membrane. This 
interaction results in inhibition of infection during any stage of binding but not 
in the next phase of post-binding. Belong to this class: 
 
1. CXCR4 and CCR5 Antagonists: The chemokine (C-X-C) motif 
receptor 4 (CXCR4) for T-tropic or X4 HIV strains, and the chemokine 
(C-C) motif receptor 5 (CCR5) for M-tropic or R5 HIV strains are gp120 
co-receptor on the host cell. CXCR4 and CCR5 normally act as the 
receptors for the C-X-C chemokine, SDF1 (stromalcell- derived factor 1), 
and the C-C chemokines RANTES (regulated upon activation, normal T-
cell expressed and secreted) and MIP1 (macrophage inflammatory protein 
1), respectively. The most prominent among the CXCR4 antagonists is the 
bicyclam AMD3100 (Fig. 1.21A)
62
, and the only compound approved by 
the U.S. Food and Drug Administration (FDA) among the CCR5 
antagonists is Maraviroc (Fig. 1.21B). 
 
 
Figure 1.21:  Host cell receptor antagonists: A. AMD3100; B. Maraviroc. 
 
1.3.2 Uncoating inhibitors 
These drugs inhibit the viral genome release and its following replication. 
Belong to this class: 
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1. Amantadine and rimantadine: Have been introduced to combat 
influenza. Uncoating of viral particles takes place in the host cell 
endosome. Acidification of the endosome promotes fusion of the viral and 
endosomal membranes, causing a structural change in the viral 
hemagglutinin (HA, antigenic glycoprotein on the surface of influenza 
viruses) and freeing the fusion peptide of its HA2 subunit to interact with 
the endosome membrane. The concerted structural change of several HA 
molecules opens up a pore through which the viral RNA passes into the 
cytosol of the cell (Fig. 1.22A).  
 
Figure 1.22:  A. Influenza virus uncoating; B. Amantadine and rimantadine  
      structures. 
 
The precise timing and the location of uncoating depends on the pH-mediated 
transition of the specific HA molecule involved. The virus-associated M2 ion 
channel protein allows the influx of H
+
 ions into the virion, which disrupts 
protein-protein interactions, resulting in the release of RNA free of the viral 
M1 matrix protein. Thus the HA mediated fusion of the viral membrane with 
the endosomal membrane and the M2-mediated release of the RNA results in 
the release of the RNA complex into the cytosol. Amantadine and rimantadine 
(Fig. 1.22B) have been shown to block the ion channel activity of the M2 
protein and thus interfere with uncoating
68
. 
2. Pleconaril: Is an antiviral drug being developed by Schering-
Plough for prevention of asthma exacerbations and common cold 
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symptoms in asthmatic subjects exposed to picornavirus respiratory 
infection. It is active against viruses in the Picornaviridae family, including 
rhinoviruses, which cause the common cold, and enteroviruses, which can 
cause diarrhea, meningitis, conjunctivitis, and encephalitis. Pleconaril 
(Fig. 1.23A) binds to a hydrophobic pocket in VP1 (Fig. 1.23B), the major 
protein which comprises the capsid (the outer "shell") of picornaviruses. 
This pocket is similar in most strains of rhinoviruses and enteroviruses. In 
enteroviruses, this prevents the virus from exposing its RNA, and in 






Figure 1.23:  A. Pleconaril structure; B. picornavirus capsid. 
 
1.3.3 Inhibitors of viral components synthesis  
A second approach is to target the processes that synthesize virus 
components after a virus invades a cell. These inhibitors have the ability to 
block the function of some viral enzymes preventing some basic steps in the 
replication process. These inhibitors include: 
 
 Viral DNA polymerase inhibitors 
Herpesviruses DNA genome can be replicated by the viral DNA 
polymerase after the latter has been expressed in the virus-infected cell. At 
present, all the antiviral agents that are available for the treatment of 
herpesvirus infections are nucleoside analogues (Fig. 1.24):  
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1. acyclic guanosine analogues, that is, acyclovir, penciclovir, ganciclovir  
and their oral prodrud forms valaciclovir, famciclovir and valganciclovir, 
respectively; 
2. thymidine analogues such as brivudin. 
  
 
Figure 1.24:  Structures of acyclovir, ganciclovir, penciclovir and brivudine. 
 
All of these compounds target the viral DNA polymerase, but before they can 
interact with viral DNA synthesis, they need to be phosphorylated 
intracellularly to the triphosphate form. The first (and, for brivudin, also the 
second) phosphorylation step is ensured by the HSV- or VZV-encoded 
thymidine kinase, or the CMV-encoded protein kinase, and is therefore 
confined to virus-infected cells, which explains the specific antiviral action of 
the established antiherpetic compounds. Subsequent phosphorylations are 
achieved by host cellular kinases. In their triphosphate form, the nucleoside 
analogues interact with the viral DNA polymerase, either as competitive 
inhibitors or as alternative substrates with respect to the natural substrate 
(dGTP for the guanosine analogues, dTTP for the thymidine analogues). If the 
acyclic guanosine analogues act as alternative substrates, their incorporation 
prevents further chain elongation (Fig. 1.25). 
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Figure 1.25:  herpesviruses mechanism of action. 
 
The moderate oral bioavailability of the acyclic guanosine analogues has been 
improved by formulating them as prodrugs. The success obtained with 
acyclovir, valaciclovir and famciclovir in the treatment of HSV and VZV 
infections has impeded further progress in this area. However, brivudin, which 
is considerably more potent than acyclovir and penciclovir as an anti-VZV 





 Viral RNA polymerase inhibitors 
One of the virus which use RNA polymerase is HCV, a positive-sense 
single-stranded RNA virus. RNA replication takes places via the viral RNA-
dependent RNA polymerase NS5B, which produces a negative-strand RNA 
intermediate. The negative strand RNA then serves as a template for the 
production of new positive-strand viral genomes. The HCV polymerase can be 
viewed as a right hand, where the palm domain contains the active site of the 
enzyme and where the fingers and the thumb are responsible for the 
interaction with the RNA. The fingertips are two loops that extend from the 
fingerdomain and that make contact with the thumbdomain (in the so called 
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closed conformation). This results in the formation of a tunnel in which the 
RNA, template as well as the nascent RNA, are contained. In the ‗open‘ 
conformation, the contact between the finger and the thumbdomain is 
disrupted; this is the virus inactive conformation
71
 (Fig. 1.26). 
 
Figure 1.26:  RNA polymerase: opened and closed conformation72. 
 
The NS5B RNA dependent RNA polymerase inhibitors are divided into: 
1. Nucleoside inhibitors (NRRIs): Intracellular phosphorylation of 
NRRIs (2‘-C methylcytidine and 2‘-C methylpurine analogues, Fig. 
1.27A) to their 5‘ triphosphate results in the formation of the active 
inhibitor of the viral polymerase. The compounds are non-obligate chain 
terminators. RNA elongation may represent the most probable target of 2‘-
modified nucleotide analogues (Fig. 1.27B), because it is more permissive 





Figure 1.27:  NS5B nucleoside inhibitors: A. Structures; B. Mechanism of action. 
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2. Non-nucleoside inhibitors: These compounds bind on the 
surface of the thumbdomain, at a position that is in the ―closed‖ enzyme 
conformation occupied by one of the fingertips. The binding of the 
compound to this cavity forces the enzyme in the ―open‖ configuration. A 
number of structurally unrelated series of non-nucleoside HCV polymerase 
inhibitors have been reported; these include, but are not limited to, 
benzimidazoles/diamides (A), disubstituted phenylalaline/thiophene 
amides (B), benzothiadiazines (C) and benzofurans (D)
71
 (Fig. 1.28). 
 
 
Figure 1.28:  Structures of NS5B non-nucleoside inhibitors. 
 
 Reverse transcriptase inhibitors 
Reverse transcriptase (RT) is essential in the replicative cycle of 
retroviruses, such as HIV, as it synthesizes the proviral DNA, which will then 
be integrated into the host cell genome and passed on to all of the progeny 
cells. The RT inhibitors are divided into: 
 
1. Nucleoside inhibitors: The substrate (dNTP) binding site of HIV reverse 
transcriptase (RT) has proved to be an attractive target for HIV nucleoside 
inhibitors. Six nucleoside analogues have been licensed as anti-HIV drugs: 
zidovudine (azidothymidine, AZT), didanosine (dideoxyinosine), 
Chapter 1                                                                                                    Introduction 
- 46 - 
 
zalcitabine (dideoxycytidine), stavudine (didehydrodideoxythymidine, 
d4T), lamivudine (3′- thiadideoxycytidine) and abacavir (Fig. 1.29A), and 
several others, such as emtricitabine and amdoxovir, are in advanced 
development. All of these dideoxynucleoside analogues act according to a 
similar ‗recipe‘, as exemplified for AZT. They must be phosphorylated 
consecutively inside the host cell by three cellular kinases (a nucleoside 
kinase, a nucleoside 5′-monophosphate kinase and a nucleoside 5′-
diphosphate kinase) to form the corresponding 5′-triphosphate derivative, 
which can interact, as a chain terminator, with the reverse transcription 
(RNA→DNA) reaction (Fig. 1.29B).  
 
 
Figure 1.29:  A. Nucleoside inhibitors of RT; B. Mechanism of action. 
 
2. Non-nucleoside reverse transcriptase inhibitors, NNRTIs: Interact with an 
allosteric, non-substrate binding (‗pocket‘) site on HIV-1 RT. At present, 
only three NNRTIs (nevirapine, delavirdine and efavirenz) have been 
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Figure 1.30:  Current clinically used NNRTIs. 
 
 Integrase inhibitors 
Gene expression (that is, transcription to viral RNA) of the genome of 
retroviruses, such as HIV, is not possible without integration of the proviral 
DNA into the host chromosome (Fig. 1.31A). So, the enzyme involved 
(integrase) has been considered an attractive target for chemotherapeutic 
intervention. Inhibiting integrase from performing its essential functions 
therefore blocks stable integration of HIV-1 DNA into the host genome and 
prohibits the establishment of viral latency within the host cell, preventing 
high-level HIV-1 replication and infection of new cells by competent virus. At 
present, the only compounds that qualify as genuine integrase inhibitors are 





Figure 1.31:  A. Integrase inhibitors: Mechanism of action (A) and structures(B).  
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 Helicase inhibitors 
Helicase are motor proteins that move directionally along a nucleic acid 
phosphodiester backbone, separating two annealed nucleic acid strands (i.e., 
DNA, RNA, or RNA-DNA hybrid) using energy derived from ATP 
hydrolysis. For example, the NS3 HCV region comprises a multifunctional 
protein that contains a serine protease at the N-terminus (that cleaves the viral 
polyprotein into functional proteins essential for replication) and a NTP-
dependent helicase at the C-terminus. HCV nonstructural protein 3 (NS3) 
RNA helicase is a promising target for developing new therapeutics. Belong to 
this class of inhibitors: QU663, a potent new selective inhibitor of the HCV 
helicase NS3, competing with the nucleic acid substrate without affecting 
ATPase function, even at high concentrations.  
QU663 (Fig. 1.32) is one of a new generation of small-molecule nucleotide-
mimicking inhibitors which are potential anti-HCV agents. Also 4,5,6,7-
tetrabromobenzotriazole (TBBT) (Fig. 1.32) hitherto known as a potent highly 
selective inhibitor of protein kinase 2, is a good inhibitor of the helicase, but 
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 The serine protease inhibitors 
Viral proteases are crucial in the life cycle of many viruses, including 
retroviruses such as HIV, herpesviruses, picornaviruses such as rhinovirus, 
and flaviviruses such as HCV. Viral proteases have therefore been favoured as 
targets for antiviral agents. Proteases cleave newly expressed precursor 
polyproteins into smaller, mature viral proteins, termed ‗functional‘ (if 
endowed with enzymatic activity) or ‗structural‘ (if part of the virion 
structure). For example, protease inhibitors licensed at present for the 
treatment of HIV infection, namely saquinavir, ritonavir, indinavir, nelfinavir, 
amprenavir and lopinavir, share the same structural determinant (Fig. 1.33A), 
a hydroxyethylene core (instead of the normal peptidic linkage) that makes 
them non-scissile peptidomimetic substrate analogues for the HIV protease. 
Non-peptidic inhibitors of HIV protease, have cyclic urea, 4-
hydroxycoumarin, L-mannaric acid or 4-hydroxy-5,6-dihydro-2-pyrone as the 
central scaffold instead of the peptidomimetic hydroxyethylene core (Fig. 
1.33A); for example, tipranavir
62
.  
Among the HCV protease (NS3/4A) inhibitors (Fig. 1.33B) there are: the 
macrocyclic peptidomimetic BILN-2061 (ciluprevir), a non-covalent inhibitor 
of NS3-4A protease inhibitor (the first HCV  protease   inhibitor   to  enter   
clinical   trials);  telaprevir  (VX-950),  a covalent-reversible peptidomimetic 
inhibitor; boceprevir (SCH-503034), an oral protease inhibitor and SCH6 
(SCH446211), a substrate-based inhibitor. Some of these compounds have 
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Figure 1.33:  HIV (A) and HCV (B) protease inhibitors. 
 
1.3.4 Assembly inhibitors 
These inhibitors prevent the assembly of viral genome and proteins into 
mature virus particles. Belong to this class antibiotic rifampicin (Fig 1.34) that 
reversibly block the cytoplasmic assembly of vaccinia virus (dsDNA virus). 
The target of rifampin is a 65-kDa, late structural viral protein, referred to as 
p65, encoded by the vaccinia virus gene D13L. At inhibiting concentrations, 
the membranes associated with the viral factories are irregularly shaped, and 
crescents and spherical, immature particles do not form. These altered 
structures have been referred to as rifampin bodies. The effects of rifampin are 
rapidly reversible, and within minutes after its removal, the membranes around 
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1.3.5 Release phase inhibitors 
The final stage in the life cycle of a virus is the release of completed viruses 
from the host cell, and this step has also been targeted by antiviral drug 
developers. Two drugs named zanamivir (Relenza) and oseltamivir (Tamiflu) 
(Fig. 1.35) that have been recently introduced to treat influenza prevent the 
release of viral particles. Influenza virus (both A and B) has adopted a unique 
replication strategy by using one of its surface glycoproteins, haemagglutinin, 
to bind to the target-cell receptor, which contains a terminal sialic acid. The 
other surface glycoprotein, neuraminidase, cleaves off the terminal sialic acid 
of the host cell receptor, allowing virus particles to leave the cell after the viral 
replicative cycle has been completed. The viral neuraminidase is therefore 
needed for the elution of newly formed virus particles from the cells. In 
addition, the viral neuraminidase might also promote viral movement through 
the respiratory tract mucus, thereby enhancing viral infectivity. So, influenza 
viral neuraminidase has been envisaged as a suitable target for the design of 
specific inhibitors. Computer-assisted drug design, based on the crystal 
structure of the influenza viral neuraminidase, led to the identification of 
zanamivir as a specific and potent inhibitor of the enzyme, and of the in vitro 
and in vivo replication of both influenza A and B virus. It was tailored to 
interact with conserved amino-acid residues within the active site of influenza 
A and B viral neuraminidase and the drug has been licensed for clinical use. 
Zanamivir has to be given topically (by inhalation), owing to its poor oral 





Figure 1.35:  Neuramidase inhibitors. 
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1.3.6 Arbidol: A broad-spectrum antiviral compound that blocks viral entry 
and replication 
Many new antiviral drugs have been licensed in recent years, most of which 
are used for the treatment of HIV infections; of the current repertoire of more 
than 30 drugs, 16 are anti-HIV, 5 are anti-CMV, 5 are anti-HSV and anti-
VZV, 1 is anti-RSV, 3 are anti-hepatitis and 4 are anti-influenza. But there is 
considerable room for improvement, as these compounds are not always 
efficacious or well tolerated. The emergence of viral resistance to drugs and 
drug-related side effects are among the main reasons for further refinement of 
antiviral drug design and development
62
. The broad-spectrum antivirals are 
less prone to developing drug resistance but their efficiency is usually a trade-
off between some cytotoxicity and anti-viral effects. Given the shortcomings 
with targeted antivirals, therapeutic regimens have in some cases shifted 
towards complementing enzyme inhibitors with less specific agents like 
inhibitors of viral fusion or viral co-receptors. Combination therapy by drugs 
with different modes of action and resistance profiles could be beneficial for a 
number of viral infections. 
One of antiviral agents that has aroused interest for its broad-spectrum of 
activity is Arbidol (ARB, Fig. 1.36). Arbidol  (ethyl-6-bromo-4 
[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-indole-
3-carboxylate hydrochloride monohydrate) is an indole compound developed 





Figure 1.36:  Arbidol structure. 
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This indole compound was certified for use in medicine for the prophilaxis 
and treatment of influenza caused by viruses of antigen types A and B and 
other acute respiratory viral infections. Beside this, the drug can also be 
administered for the complex therapy of patients with chronic bronchitis, 
pneumonia, or a recidivist HSV infection, for prophylaxis of post-operational 
infections, and for normalization of the immune status of patients, including 
those after cardiac surgery operations
80
.  
Arbidol displays a variety of biological effects such as antiviral, anti-
carcinogenic, antioxidant, radioprotective and immunostimulative effects, and 
it is also an interferon-inducer
81
. The mechanism of antitumoral activity of 
ARB is unknown but some studies have demonstrated that Arbidol has 
inhibitory effects on the development of a massive tumor induced in mice, 
probably, via the activation of immunological reactivity. Although Arbidol 
possesses a number of useful pharmacological properties, the antitumoral, 
immunomodulating and anti-oxidant aspects of its action are so far 
inconclusive; whereas its antiviral activity is very interesting.  
In fact, it exhibits a wide range and potent antiviral activity against a number 
of viruses (Fig. 1.37) including influenza A (H1N1, H2N2 and H3N2), B and C 
viruses, respiratory syncytial virus (RSV), adenovirus type 7, coxsackie B3 
virus, parainfluenza type 5 and rhinovirus type 14, avian coronavirus, 
infectious bronchitis virus and Marek disease virus, hepatitis B virus and 
hepatitis C virus. There are presently no published indications of ARB activity 
against other medically important viral pathogens like HIV-1, SARS 
coronavirus or Ebola virus. The extensive list of ARB-sensitive viruses 
encompasses RNA and DNA viruses, enveloped and non-enveloped viruses 
and pH-dependent and pH-independent viruses emphasizing a broad spectrum 
of ARB antiviral activity. 
 
Chapter 1                                                                                                    Introduction 
- 54 - 
 
 
Figure 1.37:  Broad spectrum of ARB antiviral activity. 
 
The wide spectrum of ARB‘s activity suggests that ARB targets common 
critical step(s) in virus – cell interaction.  
The anti-viral mechanism involves ARB inhibition of membrane fusion 
between the virus and the plasma membrane and in some viruses (Influenza 
viruses and HCV) also between the virus and endocytic vesicle membranes, 
resulting in a block of virus entry into target cells and uncoating
79
.  
Recent studies conducted on this compound have shown that ARB is an 
inhibitor of both fusion and replication on HCV and it inhibits acute and 
chronic HCV infection.  Moreover, it has been shown that ARB inhibits the 
cell entry of HCV pseudoparticles of genotypes 1a, 1b, and 2a in a dose-
dependent fashion. It is also conceivable that ARB could inhibit aspects of the 
HCV life cycle that are dependent on cell membranes. For example, ARB 
antiviral activity toward HCV fusion is due probably to a direct effect of ARB 
on virus-cell membrane interactions where ARB intercalates into membranes 
and adopts a consistent orientation with the formation of an ‗ARB cage‘. This 
leads to excessive stabilization of cell membranes, which become resistant to 
HCV fusion. Moreover, ARB-induced inhibition of HCV non-structural 
protein interactions with endoplasmic reticulum (ER) membranes might also 
contribute to suppression of HCV replication. Therefore, in terms of HCV 
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acute infection, the predominant mechanism of action of ARB is likely to be 
inhibition of fusion; whereas in terms of chronic infection, ARB inhibition of 
the HCV replication complex association with membranes could be the 
predominant mode of HCV suppression.  
In conclusion, the inhibitory effect appears to be due to the interaction of ARB 
with membranes and to subsequent ARB-induced membrane alterations (Fig. 
1.38), but the nature of the membrane modifications require further study. 
 
 
Figure 1.38: ARB inhibits aspects of the HCV life cycle that are dependent on cell 
membranes: (A)entry, (B)uncoating, (C)replication. 
 
In vitro biochemical studies revealed association of ARB with membranelike 
environments such as detergents and with lipid membranes. This association 
was particularly prominent at acidic pH which is optimal for viruses-mediated 
fusion. Several studies have shown that the affinity of ARB for lipid 
membranes could account for its antiviral actions, together with a differential 
level of interaction with key motifs in glycoproteins of different viruses. 
In fact, a specific effect of ARB on viral glycoproteins themselves cannot be 
excluded. Therefore, Arbidol might achieve a certain level of specificity 
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2 AIM OF PROJECT 
 
The present Ph.D. project was divided into different work parts, in a way 
that helps to understand and define the the goals of this project. In particular: 
I) Design, synthesis and characterization of Arbidol analogs using a  
convenient five-step scheme. 
II) Optimization of an alternative scheme, a convenient method to obtain 
derivatives with different scaffolds in 2-position in one step of 
reaction. 
III) Biological assays on anti-HCV and anti-HSV activity of Arbidol 
derivatives. 
IV) Evaluation of mechanism of Arbidol anti-influenza action. 
V) Synthesis and characterization of a P.E.T. radiotracer for tumor 




In addition, V step was made during a sixth-month period in the last year as a 
Ph.D visiting student at the Aberdeen University (Scotland) and it will be 
discussed in the next section. 
 
2.1 Synthesis of Arbidol analogs using a convenient five-step scheme 
 
The known biological properties of Arbidol led us to focus on its 
derivatives as potential antiviral agents. We designed and synthesised several 
novel ethyl 1H-indole-3-carboxylate derivatives, using ARB as lead 
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2.1.1 Design of derivatives 
The general design of ARB analogs was guided by the modular 
composition of this synthetic product. As mentioned in the previous chapter, 
ARB antiviral activity toward viruses is due probably to a direct effect of ARB 
on virus-cell membrane interactions, where ARB intercalates into membranes 
and induces membrane alterations. This leads to excessive stabilization of cell 
membranes, which become resistant to virus fusion and in some cases (HCV) 
to virus replication. Its tropism for membranes or membrane like environments 
is due to ARB‘s indole-derived structure and to its interaction with lipids via 
other hydrophobic and aromatic moieties on the molecule (Fig. 2.1). 
In particular: 
 
 The indole ring exhibits a preference for membrane interfaces, due to its 
flat rigid structure and to its aromaticity and establishes cation–π 
interactions with the positively charged quaternary ammonium lipid 
headgroups. 
  
 The S-phenyl group could interact with the hydrophobic fatty acid chains 
of phospholipids inside the bilayer.  
 
 The amino groups could bind the phosphate moieties of phospholipids, 
establishing a salt bridge between two adjacent phospholipid molecules as 
an ion pair complex. At low pH, these interactions increase for the 
protonation of the amino groups.  
 
 The ester group could be a substrate for hydrolysis in vivo, leading to 
intracellular accumulation of the cleaved compound. In light of the above 
considerations, ARB may be considered a prodrug which is chemically 
converted into an active drug by cellular metabolic processes
82,83
. 
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Figure 2.1:  Groups responsible of ARB interaction with membranes. 
 
In order to maintain antiviral activity we preserved the groups responsible of 
Arbidol interaction with membranes: indole ring, S-phenyl group, ester group 
and amino group. In particular, the first series of compounds contains analogs 
whose structures are closely related to ARB. The indole building block was 
simplified (Fig. 2.2) by: 
 elimination of hydroxy and bromo groups at the 5- and 6-positions of the 
indole ring; 
 shift of amino group form 4-position to 5-position to evaluate the influence 
of the polar group; 
 introduction of different substituents at the 2- and 5-position of the indole 
ring to investigate the influence of these variations on antiviral activity. 
 
Figure 2.2:  Major changes on lead compound Arbidol. 
 
In order to examine whether the nature of the amino group could have an 
effect on the potential anti-HCV activity, we introduced a variety of amine 
scaffolds, including imidazole, pyrrolidine, dimethylamine, 4-methyl 
piperazine, morpholine and homopiperazine (R2). In literature, it was 
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kept up or increased the antiviral activities
5
; on this basis, we synthesized 8 
compounds with phenylsulfonylmethyl groups at the 2-position (9a1–6). 
Subsequently, to investigate the influence of changes to the steric environment 
and the role of phenylthiomethyl group (9c1–2) and/or phenylsulfonylmethyl 
group on the antiviral activity, we introduced the methyl group at the 2-
position (9b1–2). Other changes concerned the introduction of different 
lipophilic groups at the 2-position such as the o-phenylbenzyl group (9d1–2) 
and farnesyl group (9e1–2)
 84
. On the basis of previous data, compounds 9a1–6, 
9(b-d)1–2, 9e1 were synthesised, their structures are listed in Table 2.1. 
 
Table 2.1: Structures of compounds 9a1–6, 9(b-d)1–2, 9e1. 
 
Compound            R1           R2 
9a1 Phenylsulfonyl Dimethylamino 
9a2 Phenylsulfonyl Pyrrolidinyl 
9a3 Phenylsulfonyl 4-Methyl piperazinyl 
9a4 Phenylsulfonyl Morpholino 
9a5 Phenylsulfonyl Homopiperazinyl 
9a6 Phenylsulfonyl Imidazolyl 
9b1 Hydrogen Dimethylamino 
9b2 Hydrogen Pyrrolidinyl 
9c1 Phenylthio Dimethylamino 
9c2 Phenylthio Pyrrolidinyl 
9d1 Phenylbenzyl Dimethylamino 
9d2 Phenylbenzyl Pyrrolidinyl 
9e1 Farnesyl Pyrrolidinyl 
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2.1.2 Synthetic approach 
In the development and validation of various synthetic schemes for the 
synthesis of Arbidol derivatives, the molecular diversity was taken into 
consideration as a fundamental concept as well as the easy implementation. 
Therefore, to obtain the derivatives we emphasized the importance of 
decorating the scaffold ethyl 1H-indole-3-carboxylate with different building 
blocks in 2- and 5-position. 
The preparation of these derivatives was based on design of a synthetic 
scheme to obtain products in short reaction times and in high yields. 
Therefore, Scheme 1 was designed and optimized.  
This scheme has the advantage of providing a common intermediate used in 
the last step reaction to obtain compounds with different amines in 5-position 
on indole ring and the same lipophilic group in 2-position. 
 



































Scheme 1. Synthesis of target compounds. Reagents and conditions: (a) CuI, BINOL, 
Cs2CO3, DMSO, 50°C, 5–7h, 48–56%; (b) CH3I, KOH, DMF, 0°C, 1–2h, 92–97%; 
(c) potassium vinyltrifluoroborate, 6 mol% PdCl2, 18 mol % PPh3, Cs2CO3, THF/H2O 
9:1; 85°C, 20–22 h, 80–86%; (d) Method A: OsO4, 2,6-lutidine, dioxane, NaIO4 in 
H2O, rt, 20min, 90–95%; Method B: OsO4, K3Fe(CN)6, K2CO3, Pb(OAc)4, 
Dioxane/H2O (1:1), 53%; (e) aliphatic amine, acetic acid, THF, NaB(OAc)3H, MW, 
100–130 °C, 20min, 75–95%. 
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The synthesis of target compounds 9a1–5 and 9(b-d)1–2 was achieved using a 
convenient five-step procedure starting from 4-bromo-2-iodoaniline and 
appropriate β-keto esters (3b-d), as depicted in Scheme 1. 
Moreover, since β-keto esters 3c, 3d and 3e are not commercially available, 
these compounds have been synthesized using two synthetic schemes: Scheme 










Scheme 2. Synthesis of ethyl 3-oxo-4-(phenylthio)butanoate 3c. Reagents and 
condition: (a) KOH, methanol, rt, 6h, 94%. 
 
 
Scheme 3. Synthesis of 3(d,e) β-keto esters. Reagents and condition: (a) (n-Bu)Li, 
THF, 0°C,1h, 81-90%. 
 
In the Scheme 2, the thioether 3c was prepared via etherification of ethyl 4-
chloroacetoacetate 2 with thiophenol 1c (Scheme 2). 
In the Scheme 3, coupling of the dianion (readily prepared by treatment of 
commercially available sodium ethyl acetoacetate with butyllithium) with 
brominated compounds R2Br (2d and 2e) leads to the appropriate β-keto esters 
3d and 3e. The compound 3e was used in another synthetic scheme, optimized 
during the second-third year of my Ph.D period for the synthesis of product 
9e1; instead the other β-keto esters 3c, 3d and the commercially available 
compound 3b were used in the Scheme 1. 
The compounds 3b-d were treated with 4-bromo-2-iodoaniline 4 in a copper-
catalyzed Ullmann-type coupling reaction to give the key intermediates 5b–d. 
This is the key step in the synthetic scheme because it leads to the synthesis of 
Chapter 2                                                                                    Results and discussion 
- 64 - 
 
the intermediates 5b-d with indole core and with a substituent R1 in 2-position. 
The N-alkylation of compounds 5b–d with iodomethane using the procedure 
of Kikugawa afforded in high yields the compounds 6b–d. 
These compounds were subsequently subjected to a Suzuki–Miyaura cross-
coupling reaction with potassium vinyltrifluoroborate, affording the 
intermediates 7b–d in good yields
84
.  
Several trials were made before finding the method to obtain compounds 7b-d 
with better yields and lower reaction time. 
The Method A was the first to be tested because it has the advantage to give 
intermediates 8b-d with aldehyde group in 5-position, directly from 
compounds 6b-d, bypassing the vinylation. Sequential treatment of 6b with 
KH and n-BuLi followed by the addition of DMF gave 5-formylindole 8b in 
30% yield. The low yield (30%) of this reaction step shifted attention to a 
















Method A. Synthesis of compound 8b. Reagents and conditions: (a) (1) KH (1.13 
equiv.), dry ether,0°C, 15min.; (2) n-BuLi (2.13 equiv.), -78°C, 30min.; (3) DMF (2 
equiv.), -78°C, 1h, 30%. 
 
The validation of vinylation was performed in a rigorous manner with an 
experimental design in which the variation of different parameters was 
considered, according to methods already described in the literature: nature of 
substrate carrying vinyl group, stoichiometry of reagents, reagents, solvents, 
reaction time and temperature. The reaction was carried out using as vinyl 
boronic acids tributyl(vinyl)stannane or potassium vinyltrifluoroborate  
(different equivalents), several palladium catalysts such as Pd(PPh3)2OAc or 
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PdCl2/PPh3, different reaction time and degree. These modifications of 







































85 22 80 
Table 2.2: Tested methods of vinylation. 
 
The best conditions, after these trials, were found and they are those outlined 
in the method D. The application of method D on compounds 6b-d led to the 
synthesis of compounds 7b-d in high yields. 
The combination of osmium tetroxide and sodium periodate (Lemieux–
Johnson oxidation) efficiently achieved both the oxidative cleavage of the 
vinyl group to an aldehyde group and the oxidation of the sulfide group of 
compound 7b to sulfonyl group, thereby yielding the compounds 8(a,b,d) 
(method A).  Synthesis of aldehydic compound 8c was obtained using a 
Yamamoto dihydroxylation (method B): OsO4 (0,1 equivalent) as oxidant 
agent, K3Fe(CN)6 (3 equivalent) as co-oxidant (to carry out the diol), K2CO3 
(3 equivalent) as base, Dioxane/H2O (1:1) as solvent. Then, for the oxidative 
cleavage we used Pb(OAc)4 (4 equivalent) instead of NaIO4. Lead (IV) acetate 
was used for the cleavage of the diol in place of NaIO4 which had the 
disadvantage, in combination with OsO4, to oxidize also the sulfur group of 
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phenylthiomethyl group in 2-position
89-90
. In this way we obtained compounds 
8c and 8a in yield of 53% and 5%, respectively.    
Finally, we synthesised the target compounds 9a1–5 and 9(b-d)1–2 via a rapid 
microwave-assisted reductive amination procedure that involves the formation 
of an imine and subsequent reduction with NaB(OAc)3H in a one-pot reaction. 
To obtain compound 9a5, we used N-Boc protected homopiperazine, which 
was synthesized according to Scheme 4. 
 
 
Scheme 4. Synthesis of N-Boc homopiperazine 13. Reagent and condition: (a) 
dichloromethane, 0°C, 1h, 88%. 
 
Imidazole could not be introduced into the 5-position by direct reductive 
amination with 8a. Instead, it was realized through a two-step sequence 
beginning with the reduction of the aldehyde group of compound 8a to an 
alcohol group to obtain the intermediate 10a. This was followed by treatment 
of 10a with imidazole and 1,1-carbonyldiimidazole in acetonitrile to generate 



























Scheme 5. Synthesis of compound 9a6. Reagents and conditions: (a) NaBH4 in 
methanol, THF, rt, 1 h, 91%; (b) imidazole, 1,1-carbonyldiimidazole, acetonitrile, 
reflux, 16 h, 67%. 
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Compound 9e1 could not be synthetized with Scheme 1. Therefore, for this 
synthesis the scheme below was used. 
 
2.2 Alternative synthetic scheme 
 
In order to have greatest speed in the target compounds synthesis, during 
the second year and the first part of third year, another synthetic scheme was 
optimized (Scheme 6). This scheme, unlike Scheme 1, is convenient to obtain 
derivatives with the same amino group in 5-position on indole ring but 
different substituents in 2-position. 
The starting material of this synthetic scheme is PABA (p-amino benzoic 
acid). In a seven-step synthesis, this compound led to the synthesis of N-
methyl 2-iodioaniline replaced in para-position with the appropriate amino 
group (20). The latter, interacting with various β-keto esters, will lead to the 
synthesis of derivatives with different groups in 2-position (R1). Therefore, we 
can say that the Schemes 1 and 6 are both important for the synthesis of 
derivatives with ethyl 1H-indole-3-carboxylic core variously substituted in 2- 
and 5-position. The Scheme 1 can be used for the synthesis of derivatives with 
different amine in 5-position; while the Scheme 6 can be used for the 
synthesis of derivatives with different substituents in 2-position.  
Really, we used Scheme 6 to synthesized target compound 9e1, which has 
farnesyl group in 2-position and pyrrolidine in 5-position.  
In this scheme, PABA was subjected to a ioduration to give compound 14 (4-
amino-3-iodobenzoic acid)
91
, followed by reduction to alcool 15 and then by 
subsequent oxidation to aldehyde 16. These steps of reduction and oxidation 
were made using the reducing agent Lithium aluminium hydride and the 
oxidant agent Pyridinium dichromate, which oxidizes primary alcohols to 
aldehydes and secondary alcohols to ketones
92-94
.  
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Scheme 6. Synthesis of target compound 9e1. Reagents and conditions: (a) NaIO4, 
NaCl, KI, CH3COOH/H2O 9:1, rt, over night, 70%; (b) LiAlH4, Diethyl ether, from 
0°C to rt, 16h, 81%; (c) Pyridinium dichromate, DCM, rt, 2h, 80%; (d) Acetic 
anhydride, DCM, rt, 30h; 87%; (e) NaH, CH3I, THF, from 0°C to rt, 3h, 75%; (f) 
Pyrrolidine, CH3COOH, NaB(OAc)3H, THF, MW, 130 °C, 10min, 85%; (g) NaOH, 
EtOH, H2O, reflux, over night, 91%. (h) CuI, BINOL, Cs2CO3, DMSO, 50°C, 5–7h, 
45%. 
 
Compound 16 was treated with acetic anhydride to afford the acetylated 
compound 17 in high yield
95
. The N-methylation using sodium hydride and 
methyl iodide afforded in good yield compound 18.  
Then it follows a reductive amination on aldehyde to give compound 19 with 




This compound  is precursor of the indole compounds and it was treated with 
β-keto ester 3e in a copper-catalyzed Ullmann-type coupling reaction to give 
final product 9e1 with the farnesyl group in 2-position.  
Using different β-keto esters, you can obtain several compounds variously 
substituted in 2-position. Therefore, the Scheme 6 is a quick and efficient 
method for the synthesis of indole compounds with different groups in 2-
position while leaving the group in 5-position. 
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2.3 Biological assays 
 
Compounds 9a1–6 and 9b1–2 were tested for their antiviral activity against 
Hepatitis C virus (HCV) genotype 2a and Herpes simplex type 1. Moreover, 
for all synthesized compounds, it was assessed if they are selective inhibitors 
of HCV.  
 
2.3.1 Anti-HCV analysis 
Target compounds 9a1–6, 9b1–2 and Arbidol were tested in vitro in Huh-7.5 
cells for cytotoxicity and anti-HCV activity, specifically, the ability to inhibit 
the entry and replication of HCV.  
For this anti-HCV analysis, a luciferase assay (Bright-Glo Luciferase assay 
system) was made. This is a convenient assay for reporter gene applications, 
often used to investigate the replication cycle of different viruses and for 
identification of compounds with antiviral activity. Synthetic analogs, and 
their lead Arbidol, were tested using HCV subgenomic particles containing the 
luciferase gene as reporter gene to infect hepatoma cells. This study evaluated 
the potency of our inhibitors measuring viral infection indirectly, or rather 
through estimation of the enzyme activity. Therefore, in the absence of viral 
inhibitors the infection occurs, the virus enters in the cells, replicates and 
produces luciferase, whose signal is measured indirectly by indicating the 
amount of viral particles contained in the cells. In the presence of antiviral 
drugs, therefore, this signal is inhibited. Moreover, cytotoxicity induced by the 
test compounds in cultures of cells was also determined. The toxicity of 
compounds 9a1–5 and 9b1–2 in Huh-7.5 cells was evaluated by CellTiter-Blue 
Viability Assay (Promega) a homogeneous, fluorometric method for 
estimating the number of viable cells present in multiwell plates
85
.  
The properties of these compounds are summarized in Table 2.2.  
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a
 EC50 is 50% effective concentration in Huh-7.5 cells. 
b
 CC50 is 50% cytotoxic concentration. 
c
 Selectivity index (SI: CC50/EC50). 
d
 No cytotoxic activity at 50 μM concentration. 
e
 % of inhibition at 100 µM concentration: 95% on entry and 80% on replication. 
 
Several compounds exhibited inhibitory effects on HCV comparable to 
Arbidol. Compound 9a2 showed the most potent in vitro anti-HCV activity. Its 
EC50 (5 and 3 μM) values in both entry and replication assays were highly 
comparable to those of Arbidol (2 and 1 μM, respectively). Interestingly, 
compound 9a2 did not display cytotoxicity at 50 μM concentration, while at 
100 μM concentration an inhibition of cell viability of 95% and 80% on entry 
and replication, respectively, was detected. Therefore, compound 9a2 
selectivity indices (>10, >16.7) were higher than those of Arbidol (6, 15). 
The analogs 9a3 and 9b1 also exhibited significant efficacy against HCV 
(structures were listed in Fig. 2.3). Their EC50 values on entry were 8 and 8 
μM and on replication were 4 and 3 μM, respectively, which were higher than 
the positive control Arbidol. Also in these cases, the selectivity indices of 9a3 
and 9b1 on HCV entry (>6.3) and on HCV replication (>12.5, >16.7) were 
higher than or comparable to those of ARB. 
 
 
Figure 2.3: Chemical structures of typical compounds that showed significant anti-
HCV activity. 
 
Compounds 9a1–6, with the same groups in position 1–3 but different ammines 
in 5-position, showed an IC50, on entry and replication, in the range from 3 to 
21 μM concentration. These results suggested that the different amines 
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introduced at the 5-position had a relatively minor influence on the antiviral 
activities. 
Moreover, the imidazolyl group in compound 9a6 seemed to shift the 
selectivity toward inhibition of HCV entry, to reduce the potency against HCV 
replication and to enhance the cytotoxicity. 
Compounds 9b1 and 9b2 exhibited strong anti-HCV effects. This revealed that 
the elimination of the phenylsulfonyl moiety preserved the anti-HCV activity. 
These preliminary results demonstrated that the removal of the 6-bromo and 5-
hydroxy groups from the indole ring of Arbidol did not have an influence on 
its anti-HCV efficacy. This implies that these groups might not be the antiviral 
pharmacophores. 
In summary, according to the above results, the following conclusions can be 
drawn: 
1 The elimination of the phenylsulfonyl group at the 2-position seemed 
to preserve the antiviral activities. 
2 Compounds with different amines introduced at the 5-position did not 
show a wide variation in anti-HCV effects. 
3 The 6-bromo and 5-hydroxy groups might not be the pharmacophores 
responsible for the anti-HCV effects. 
Despite several changes made to the Arbidol structure in our derivatives, the 




2.3.2 Anti-HSV analysis 
Target compounds 9a1–6, 9b1–2 and Arbidol were tested in vitro in the 
human keratinocyte (HaCaT) cells for anti-HSV activity. 
To evaluate the antiviral activity on HSV type-1 of derivatives, two assays 
were made: plaque assay and assay for antiviral activity. 
The first assay was performed to choose the best concentration of Arbidol and 
its analogues to test for the antiviral activity. In the plaque assay, Human 
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Keratinocyte cells (HaCat) were treated with Arbidol and derivatives at 
different concentration (12, 6, 3 and 1 M) for 3 h. As positive control  a 
treatment with acyclovir 10M was used. The cells were then washed with 
PBS and infected with HSV-1 at MOI (low multiplicity of infection) of 0.001 
PFU (plaque-forming units )/ cell. After 1 h of incubation at 37 °C (adsorption 
period), the unadsorbed virus was removed and the plaque number calculated. 
All substances at all concentrations tested showed a reduction of PFU (the 
number of particles able to form plaques and so infectious particles) compared 
to that obtained in the untreated infected cell. The best concentration resulted 3 
M used for all the other experiments. At this concentration Arbidol and 
compounds 9b2, 9b1 and 9a2 showed the best anti-HSV activity with a 
reduction of infectivity (Fig. 2.4), vs the untreated infected cells, of about: 
42%, 35%, 46% and 49%, respectively. The other target compounds did not 
show a substantial antiviral activity with a reduction of infectivity under 35%. 
 
 
Figure 2.4:  Plaque assay. 
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The assay for antiviral activity was made in order to identify which phase of 
HSV-1 replication (preadsorption/adsorption or post-adsorption period) was 
affected by Arbidol and its analogues.  
Therefore, it was evaluated the virus yield detected after 24 and 48 h from the 
infection of keratinocyte cultures with HSV-1, treated or not with Arbidol and 
derivatives at 3 M. In three different set of experiment the molecules were 
added 1) 3h befor /during infection (preadsorption/adsorption), 2) during 
infection (adsorption) and 3) during post infection (post-adsorption) period.  
In this assay, good results (Fig. 2.5) were obtained pretreating keratinocytes 
for three hours and adding the molecules during the adsorption period.  
Data represent the virus yield detected at 24 and 48h after infection in the 
presence or absence of  ARB and derivatives. Values indicate the percent of 
inhibition of virus production in treated cells compared to untreated infected 
controls (PFU%).  
   
 
Figure 2.5:  Assay of antiviral activity. 
 
This proves that Arbidol analogues work in the first step of HSV replication 
cycle (entry). 
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In the other experimental conditions there are no obvious differences between 
treated and untreated infected controls. This proves no activity of compounds 
on the HSV replication. Therefore, some Arbidol analogues have a good and, 
in two compounds, higher anti-HSV-1 activity than lead compound (9b1 and 
9a2). Moreover, the most active compounds on HSV-1 have the best activity 
also on HCV. This reveals that Arbidol derivatives, such as the lead 
compound, have a broad antiviral spectrum. 
 
2.3.3 Evaluation of the selective anti-HCV activity 
An evaluation of the selective antiviral activity of compounds 9a1–6, 9(b-
d)1–2 and Arbidol on the replication of Hepatitis C virus (genotype 1b, Con1 
strain) in Huh cells (subtype 5-2) was made. To assess whether synthesized 
compounds and/or Arbidol can be retained as selective inhibitors of HCV 
replication, a replicon system was used.  
To fully understand the results obtained with this assay, a short explanation on 
replicon system should be made.  
The HCV replicon system is a piece of viral RNA (replicon) that self-
replicates in the host cell without the need of infecting cells and also not 
producing new infectious virus particles (it is a virus particle-free system). 
This multiplication of the replicon is extremely dependent on the good health 
of the host cell.  
The cell viability is shown with the green line. In detail, a compound can be 
retained as a selective inhibitor (Fig. 2.6) of the replication of HCV when: 
1.      It produces an EC90; 
2.      It inhibits the HCV replicon >50% (preferably >90%) at a concentration 
where the green curve is at 95-100%; 
3.      The SS (selectivity surface = the surface delineated by the green, red and 
50% horizontal) should be as high as possible, meaning >30 or so. 
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Figure 2.6:  Example of how the curve looks for a selective inhibitor of HCV 
replication. 
 
After a detailed screening, it was revealed that none of the compounds can be 
retained as selective inhibitor of HCV replication in the replicon system.  
In fact, what you can see is that for all of compounds, the green line goes 
down with increasing concentration of compound. This can be seen also in the 
lead compound Arbidol (Fig. 2.7).  
 
 
Figure 2.7:  Diagram of Arbidol in the selectivity assay: a maximum of 71% 
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Moreover, none of compounds produce an EC90 and all results are summarized 
in Table 2.3. 
 
Table 2.3: Selective antiviral activity of target compound on HCV replication.  
Compound Unit CC50 EC50 EC90 SI SS TI %Inh. at [] 
Arbidol µg/ml >100 27.7 ND >3.61 >6.52 >3.63 71 72.3 
9a1 µg/ml    45.7 8.21 ND  5.57  11.8  8.83 79.7 23 
9a2 µg/ml    18.2 6.01 ND  3.03  4.5  2.17 68.7 13.2 
9a3 µg/ml   17.6 8.96 ND  1.96  2.46  0.72 66.8 15.2 
9a4 µg/ml 53 10.7 ND  4.95  12.8  8.92 79.4 37.2 
9a5 µg/ml  44.6  10.9 ND  4.07  9.58  5.84 80.9 19.4 
9a6 µg/ml  31.1  7.94 ND  3.92  6.2  3.68 74.3 16.4 
9b1 µg/ml  14.3 5.44 ND  2.64  3.58  1.51 67 12.1 
9b2 µg/ml   30.5 8.52 ND  3.58  5.85  3.24 73 16.2 
9c1 µg/ml   2.58 <0.8 ND >3.22 >11.2 >5.72 79.6 1.65 
9c2 µg/ml   4.28 <0.8 ND >5.36 >10.7 >7.82 74.9 2.59 
9d1 µg/ml <0.8 <0.8 <0.8 ND ND ND 96.2 20 
9d2 µg/ml <0.8 <0.8 <0.8 ND ND ND 100 100 
ND= not determined. 
CC50= 50% Cytostatic/Cytotoxic Concentration (concentration at which 50% adverse 
effect is observed on the host cell). 
EC50= 50% Effective Concentration (concentration at which 50% inhibition of virus 
replication is observed). 
EC90= 90% Effective Concentration (concentration at which 90% inhibition of virus 
replication is observed). 
SI= Selectivity Index (CC50/EC50). 
SS= Selectivity Surface (integrated surface delineated by the green curve, the red 
curve and the 50% horizontal). 
TI= Therapeutical Index (SS * 10logSI). 
 
For two compounds, exactly 9d1 and 9d2, we had an extreme case in which the 
green curve is at the bottom (the cells are death) and the red one at the top 
(Fig. 2.8). In this case the virus replicon cannot replicate because its 
replication is highly dependent on the viability of the host cell itself.  
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Figure 2.8:  Diagrams of compounds 9d1 and 9d2 in the selectivity assay: extreme 
cases in which all cells are death. 
 
It's also interesting to note that compounds 9c1-2 (not yet tested in the above 
assays), although not selective replication inhibitors, have an EC50 lower than 
the other compounds (Fig. 2.9), including the lead compound. Moreover, 
unlike other compounds, these have an inhibitory activity even at low 
concentrations when the cell viability is high . 
 
 
Figure 2.9: Diagrams of compounds 9c1-2 in the selectivity assay. At low 
concentrations (<1μg/ml) we have high green line and high red line. 
 
Through these results, we demonstrated that Arbidol and derivatives are not 
HCV selective inhibitors, but their anti-HCV activity, also as replication 
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2.4 Evaluation of mechanism of Arbidol anti-influenza action 
 
As previously mentioned, Arbidol is a broad-spectrum antiviral agent 
lunched in Russia for the prophylaxis and treatment of influenza A and B. It 
acts in the early stages of the replication cycle of these viruses, such as 
membrane fusion between virus and host cell (which occurs at pH 7.4) and 
between the virus and endosome (which occurs at pH 5 and it is responsible 
for the release of the viral genome). There are also experimental evidence that 
ARB does not affect viral neuraminidase (NA, a surface protein of influenza 
virus) activity or viral transcription/translation and nor does ARB inhibit 
adsorption. Influenza virus haemagglutinin (HA, other surface protein) 
mediates viral envelope fusion with endosomal membranes. Fusion requires 
HA conformational changes that occur only at acidic pH; these changes lead to 
the exposure of the N-terminal fusion peptide contained in the HA2 subunit of 
HA, permitting its interaction with the target endosomal membrane (Fig. 
2.10).  
 
Figure 2.10: HA conformations: a) At a pH of 7.0, the N-terminus of each HA2 
subunit is tucked into a crevice in the spike. This is the normal HA 
conformation when a viral particle encounters the surface of a host cell. b) At 
the pH of 5.0 within an endocytic vesicle, HA undergoes several 
conformational changes that cause a major rearrangement of the subunits. As 
a result, the three HA2 subunits twist together into a three-stranded coiled-coil 
rod that protrudes more than 13 nm outward from the viral membrane with the 
fusion peptides at the tip of the rod
97
.  
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ARB affects early post-adsorption stages of virus replication with possible 
involvement of the second surface viral protein, the haemagglutinin (HA). 
Arbidol could act increasing influenza virus HA stability and preventing low 
pH induced HA transition to its fusogenic state, thus blocking infection at the 
viral fusion stage. 
To support this hypothesis there are recent data in literature in which ARB-
resistant mutants, selected from the most sensitive reassortant, possessed 
single amino acid substitutions in the HA2 subunit which caused an increase 
in the pH of fusion and the associated conformational change in HA. 
Moreover, Xray crystallography structure analysis, that reveals how ARB 
stabilizes the HA molecule, have not yet been made
79,98
. 
To evaluate the interaction of Arbidol with the N-terminal hydrophobic fusion 
domain of Haemagglutinin (HA), during second year of my Ph.D period the 
peptide host-guest (P20H6) was synthesized and Circular dichroism studies 
were made.  
 
2.4.1 Synthesis of host-guest peptide (P20H10) 
In the host-guest peptide (P20H6), the fusion domain (guest) was linked via 
a flexible linker to a very polar, solubilizing (host) peptide to remove the 
strong tendency of the domains to aggregate in solution and in membrane 
environments. 
The fusion domain of HA in the form of host-guest peptide P20H6 has the 
following sequence: GLFGAIAGFIENGWEGMIDGGGKKKK, in which 
multiple lysine residues increase the solubility of the peptides and facilitate 
binding to negatively charged membranes
99
. 
The synthesis of peptide (P20H6) was made with techniques of Solid Phase 
Peptide Synthesis (SPPS). This synthetic strategy provides for the anchorage 
of the growing peptide chain to an insoluble polymeric support (resin) with 
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linkers, which are anchored covalently to the first amino acid through the free 
carboxyl group, leaving the amino group properly protected. 
The general principle of SPPS is the repetition of cycles of deprotection and 
coupling: the amino group of the first residue, anchored to the resin is 
unprotected and reacts with the free carboxyl of a new amino acid, also amino-
protected. In this way, the peptide remains "attached" to the support for the 
duration of the cycles of synthesis, allowing you to replace the intermediate 
steps of purification by simple washing and filtration. 
At the end of synthesis, the compound is removed from the media and they are 
removed once protections introduced on the groups in side chain. This type of 
technique has several advantages compared to the synthesis in solution. First, 
it allows to overcome the problems arising from the possible insolubility of 
peptide intermediates in organic solvent used. Secondly, it allows easy 
removal of excess reagents and by products by simple washing and filtration 
after completion of each reaction, because the peptide is completely insoluble 
in all synthetic stages. 
The synthesis is performed in a single reactor, this will avoid loss of material 
and obtain high yields in the final products, utilizing large excesses of reagents 
to drive reactions to completion. Disadvantages are represented by the lack of 
methods for quantification in real-time of reactions. Moreover the yield of the 
single reactions must be kept as close as possible to 100%. It is evident that 
the purity of the final product will be higher when greater is the yield of 
individual reactions cyclically repeated to assemble the peptide. 
Modeling kinetics of deprotection and condensation reactions are very 
complex because the pores of the particles of support are gradually obstructed 
by the growing chains. These chains, in turn, tend to assume an ordered 
structure in space resulting in mutual interactions and then they aggregate 
hiding the reactive terminal; in addition, as a result of inter-chain interactions, 
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the structure of the porous matrix may collapse, drastically reducing the rate of 
diffusion of reagents and solvents through the matrix. 
Given the multiple benefits that this method of synthesis has, a large number 
of resins has been developed. The choice of solid support and appropriate 
protecting and activating groups is made on the basis of the amino acid 
sequence to be synthesized. The resin must meet certain requirements, such as 
ease of reaction with the acid group of the first amino acid and stability, which 
must maintain the conditions for removing protecting groups. This suggests 
that, if, for example, the protecting group is basic-labile, the resin must be 
acid-labile.  
Among the resins available the choice fell on Rink-amide, a polystyrene resin 
copolymerized with 2% of divinylbenzene (DVB).  
Latter aims to create cross-links to make the resin insoluble in organic 
solvents. The level of crosslinking can not exceed 2% to not harden the resin, 
which should be swellable like a sponge when wet by the solvent to allow easy 
movement of the reagents inside. The resin used is derivatized with the linker 




Figure 2.11: Rink amide resin linker. 
 
Moreover, this resin is acid-labile, so it is stable in basic conditions. This 
means that it is not affected by changes in the conditions of removal of 
protecting groups of amino function in the amino acids considered, 
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representing 9-fluorenylmethyloxycarbonyl (Fmoc). So it can be done in basic 
environment for piperidine.  
In addition, it is necessary to use amino acids protected with groups in the side 
chains and to remove them only in highly acidic conditions, used during the 
terminal phase of cleavage, with which, peptide is removed from the resin 
with acidolysis (Fig. 2.12) with trifluoroacetic acid (TFA). 
 
 
Figure 2.12: Solid-phase peptide synthesis and acidolysis with TFA. 
 
The first operation performed was the solvation of the resin in DMF (N, N-
dimethylformamide). This operation has the aim to expand the resin, and make 
more accessible the reaction sites. Subsequently it was necessary to remove 
the Fmoc group to release the amino function of the linker, which is essential 
for the next reaction; the removal was done using a solution of 25% piperidine 
in DMF, as the subsequent steps of deprotection of the amino group of the 
growing chain. 
The first amino acid, Fmoc-Lys-(Boc)-OH as well as the following, were then 
coupled according to standard protocols of solid phase peptide synthesis.  
The coupling was carried out using as coupling agents salts of uronic such as 
HOBT (N- Hydroxybenzotriazole) and HBTU (O-Benzotriazole-N,N,N‘,N‘-
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tetramethyl-uronium-hexafluoro-phosphate) in presence of a tertiary base, 
DIPEA (N,N-Diisopropylethylamine).  In some cases we used DCC (N,N’-
Dicylohexylurea) instead of HBTU (Fig. 2.13). 
 
 





-Fmoc group of each amino acid was removed by 25% piperidine in 
DMF (Fig. 2.14). The amino acid sequence was thus assembled by alternating 
cycles of deprotection with cycles of coupling. 
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Figure 2.14. Removing of Fmoc. 
 
After each coupling, to determine the completeness, and after each 
deprotection, to verify the complete removal of the Fmoc protecting group, the 
Kaiser test was done. The separation of the final peptide from the resin and 
simultaneous removal of other protecting groups in the side chain were 
performed using a mixture of TFA (trifluoroacetic acid) 90%, TIPS 
(Triisopropylsilane) 5% and H2O 5% (Fig. 2.15).  
 
 
Figure 2.15. Diagram of synthesis of peptide. 
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The resin was removed from the solution by filtration and the crude peptide 
was obtained by precipitation in diethyl ether in cold, giving a white powder. 
The crude peptide obtained was purified on reversed phase preparative RP-
HPLC column and chemical-physical properties and purity of these 
peptidomimetics were assessed by ESI / MS and RP-HPLC. 
 
2.4.2 Circular dichroism studies 
Circular dichroism (CD) refers to the differential absorption of left and 
right circularly polarized light. This phenomenon is exhibited in the absorption 
bands of optically active chiral molecules. CD spectroscopy has a wide range 
of applications in many different fields. 
This technique allows to measure the variation of the polarization after 
passage of light through a chiral substance. In the circular dichroism circularly 
polarized light is used. This can be dextrorotatory (R) or left-handed (L) and 
the interaction with a chiral center involves more interaction with the 
component L or R. Due to the interaction with the molecule, the electric field 
vector of the light traces out an elliptical path after passing through the 
sample. The ellipticity is the parameter measured in CD spectroscopy. 
The main components of a used CD spectropolarimeter are: a light source that 
sends light to a monochromator. The monochromatic radiation reaches the 
linear polarizer and emerges as linearly polarized radiation. 
Two radiations of this type affect a modulator electro, giving rise to a 
circularly polarized light and this affects the sample. From the sample, the 
light exits as elliptically polarized and heads toward the detector. After the 
detector, an amplifier / signal processor and recorder are contained. 
Graphs are obtained by the rotation and they, when properly interpreted, 
provide useful information about the molecule conformation. The CD 
spectrum of proteins can reveal important characteristics of their secondary 
structure.  
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CD spectra can be readily used to estimate the fraction of a molecule that is in 
the alpha-helix conformation, the beta-sheet conformation, the beta-turn 
conformation, or some other (e.g. random coil) conformation (Fig. 2.16).  
 
 
Figure 2.16: Diagram of peptide conformations (α, β and random coil). 
 
These fractional assignments place important constraints on the possible 
secondary conformations that the protein can be in. CD cannot, in general, say 
where the detected alpha helices are located within the molecule or even 
completely predict how many there are. Despite this, CD is a valuable tool, 
especially for showing changes in conformation. It can, for instance, be used 
to study how the secondary structure of a molecule changes as a function of 
temperature, of the concentration, of denaturing agents or of agents that 
interact with protein.  
Circular dichroism (CD) experiments were performed at 25°C on a 810-Jasco 
spectropolarimeter using a quartz cuvette with a path length of 1 mm. 
CD spectra were performed on peptide in H2O at 200 µΜ concentration, at pH 
5 and 7, in lysophosphatidylcholine micelles (LPC), with or without Arbidol. 
In addition, the estimation of the secondary structure composition was carried 
out using the algorithm K2D by DichroWeb.  
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CD spectra, in figure 2.17 and 2.18, shows peptide curve at pH 5 and 7, in 
LPC micelles, alone and in the presence of Arbidol in the molar ratio of 1:1 
and 1:5 peptide/Arbidol (the choice of the molar ratio 1:5 peptide/Arbidol is 
due to peptide molecular weight that is about 5 times higher than those of 
Arbidol). 
Figure 2.17 shows that the CD spectra of peptide, alone and at pH 5, is an 
alpha helix (100%). After addition of Arbidol in molar ratio 1:1, the peptide 
adopts an alpha helix of 90%. Finally, a transition from alpha helix to β sheet 
(90%) occurs after an increase of Arbidol concentration, in particular using a 
molar ratio 1:5 peptide/Arbidol. 
 
 
Figure 2.17: Circular dichroism of peptide P20H6 (SG1) in LPC at pH 5, 
alone and in molar ratio 1:1 and 1:5 with Arbidol.  
 
Figure 2.18 shows that the CD spectra of peptide, alone and at pH 7, is an α-
helix (100%). When Arbidol is in molar ratio 1:1 with peptide, the peptide 
curve still adopts an α-helical conformation (100%). Moreover, the addition of 
Arbidol in higher concentration, using a molar ratio 1:5 peptide/Arbidol, leads 
to a transition to a more disordered conformation (40% alpha helix and 60% 
random coil). 
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Figure 2.18: Circular dichroism of peptide P20H6 (SG1) in LPC at pH 7, 
alone and in molar ratio 1:1 and 1:5 with Arbidol.  
 
From this first studies we can deduct that Arbidol interacts with the 
haemagglutinin fusion domain at pH5 and 7, through changes in the secondary 
structure of peptide.  
In addition, the prominent interaction is at fusiogenic pH in which we have a 
transition from α-helix to β sheet and this transition is directly linked to the 
increase of Arbidol concentration. 
Moreover, other CD studies were performed to assess if the changes in the 
secondary structure of peptide were due to the presence of bromine in the 
Arbidol molecule and not to its antiviral activity. Therefore, CD spectra on 
peptide were made at pH 5 and 7, and  in presence of another compound with 
bromine on its structure, 4-Br-2-iodoaniline (Fig. 2.19-2.20).  
CD spectra of peptide in presence of this brominated molecule showed not 
significant changes in the secondary structure of peptide. In fact, in both pH of 
5 and 7, peptide curve was always an α-helix (100%) such as in the only 
peptide. 
Chapter 2                                                                                    Results and discussion 
- 90 - 
 
 
Figure 2.19: Circular dichroism of peptide P20H6 (SG1) at pH 5 in LPC, 




Figure 2.20: Circular dichroism of peptide P20H6 (SG1) at pH 7 in LPC, 
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During the last year of my Ph.D., I spent six months at the University of 
Aberdeen where I worked to the synthesis of a PET (Positron Emission 
Tomography) radiotracer for tumour hypoxia: the [
18
F]1-α-D-(5-Fluoro-5-





F-FAZA is currently the gold standard for PET Imaging of diseases 
characterized by hypoxia (solid tumours, ischemia, stroke), but ), but it is not 
routinely used and synthesized in Scotland. The work done is an important 
starting point for the introduction of 
18
F-FAZA in Scotland with the aim of 
using it in clinical imaging and research.  
In particular, following a detailed bibliography research on this compound and 
its synthesis, that is not fully reported, and a subsequent optimization of the 
synthetic scheme used, the 
18
F-FAZA precursor was obtained: 1-α-D-[5’-O-
Toluenesulfonyl-2’,3’-Di-Oacetylarabinofuranosyl]-2-nitroimidazole (DAcTs-
AZA).  
Before explaining the chemistry, it is appropriate to provide a wider overview 
on tumour hypoxia and radiotracers used in PET, in a way that helps to 
understand and define the goals of this project. 
 
3.1 Tumour hypoxia 
 
Tissue hypoxia results from an inadequate supply of oxygen (O2) that 
compromises biological functions. Structural and functional abnormalities of 
the tumour vasculature, together with altered diffusion conditions inside the 
tumour, seem to be the main causes of tumour hypoxia. 
Evidence from experimental and clinical studies points to a role of tumour 
hypoxia in tumour propagation, resistance to therapy and malignant 
progression. The prevalence of hypoxic areas is a characteristic feature of 
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locally advanced solid tumours and has been described in a wide range of 
human malignancies, including cancer of the breast, uterine cervix, vulva, 
head and neck, prostate, rectum, and pancreas as well as in brain tumours, soft 
tissue sarcomas and malignant melanomas.  
Up to 50–60% of locally advanced solid tumours may exhibit hypoxic and/or 
anoxic tissue areas that are heterogeneously distributed within the tumour 
mass. These hypoxic areas result from an imbalance between oxygen supply 
and consumption which is caused by abnormal structure and function of the 
microvessels (Fig 3.1) supplying the tumour (causing acute hypoxia), 
increased diffusion distances between the nutritive blood vessels and the 
tumour cells (causing chronic hypoxia), and reduced O2 transport capacity of 
the blood due to the presence of disease- or treatment-related anaemia.  
Recent studies have demonstrated a clear relevance of this hypoxic 
microenvironment to tumour-associated metabolic alterations, which are 





Figure 3.1: Normal vasculature (a), abnormal tumour vasculature (b) and chronic 
tumour hypoxia (c). 
 
Hypoxic cells are viable, oxygen deficient, cells that are generally 2.5 to 3-fold 
more radioresistant than well-oxygenated cells to the cytotoxic effects of 
ionizing radiation (oxygen effect).  
Hypoxia develops in many solid tumours, leading to the induction of adaptive 
genomic transcriptional and post-translational changes that promote the 
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establishment of an aggressive phenotype which induces metastatic potential, 
promotes angiogenesis and supports local disease progression.  
Inadequate angiogenesis and compression of blood and lymphatic vessels in 
rapidly proliferating tumour cells change the composition and structure of the 
extracellular matrix (ECM), which effectively reduces perfusion of the tumour 
and, consequently, decreases the delivery of the drugs to the hypoxic area.  
Since hypoxic tumour cells have an aggressive and treatment-resistant 
phenotype, they respond poorly to radiotherapy (external beam radiotherapy; 
XRT) and are major determinants of XRT failure.  
In this respect, tumour hypoxia has been associated with an aggressive tumour 
phenotype, poor response to radiotherapy and chemotherapy, increased risk of 
invasion and metastasis, and worse prognosis in advanced squamous cell 
carcinoma of the cervix, head and neck, and soft-tissue sarcomas. 
This necessitates early identification of hypoxic tumour cells and aggressive, 




Many of the adaptations to tumour hypoxia seem to be orchestrated by the 
transcription factor hypoxia-inducible factor (HIF)-1, which has been verified 
as a master regulator of oxygen homeostasis under hypoxic conditions.  
Its oxygen-dependent activity is regulated in a delicate interplay between 
several factors in which a family of prolyl hydroxylase domain-containing 
proteins or PHDs, the von Hippel-Lindau (VHL) tumour suppressor protein 
(pVHL) and an E3 ubiquitin ligase complex, amongst many others, play an 
important role (Fig. 3.2).  
The HIF-1 pathway mediates critical hypoxic adaptations by the induction of 
target genes involved in glucose metabolism, angiogenesis, erythropoiesis and 
apoptosis.  
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These target genes include vascular endothelial growth factor (VEGF), 
facilitative glucose transporters (GLUTs), hexokinases (HKs), erythropoietin 
(EPO), carbonic anhydrase IX (CAIX), etc. 
 
 
Figure 3.2: HIF-1α regulation by proline hydroxylation: (a) In normoxia, hypoxia-
inducible factor (HIF)-1α  is hydroxylated by proline hydroxylases (PHD1, 2 and 3) 
in the presence of O2, Fe
2+, 2-oxoglutarate (2-OG) and ascorbate. Hydroxylated HIF-
1α (OH) is recognised by pVHL (the product of the von Hippel–Lindau tumour 
suppressor gene), which, together with a multisubunit ubiquitin ligase complex, tags 
HIF-1α with polyubiquitin; this allows recognition by the proteasome and subsequent 
degradation. Acetylation of HIF-1α (OAc) also promotes pVHL binding. (b) In 
response to hypoxia, proline hydroxylation is inhibited. VHL is no longer able to bind 
and target HIF-1α for proteasomal degradation, which leads to HIF-1α accumulation 
and translocation to the nucleus. There, HIF-1α dimerises with HIF-1β, binds to 
hypoxia-response elements (HREs) within the promoters of target genes and recruits 
transcriptional co-activators such as p300/CBP for full transcriptional activity. A 
range of cell functions are regulated by the target genes, as indicated. Abbreviation: 
CBP, CREB-binding protein; Ub, ubiquitin105. 
 
The resulting adaptive changes in the proteome and genome of the tumour 
cells are believed to lead to more aggressive clones which are better adapted to 
survive in their compromised situation. Subsequent selection and clonal 
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expansion of these clones lead to a more adapted and aggressive tumour cell 
population. 
As noted above, the presence of tumour hypoxia appears to impair the 
effectiveness of common anticancer therapies like radiotherapy (RT) and 
chemotherapy.  
Hypoxia-induced radioresistance is multifactorial. Besides the above-
mentioned proteomic and genomic changes that most likely contribute to 
resistance by increasing the number of mutated cells that are more resistant to 
apoptosis and by causing upregulation of several stress proteins, the main 
reason for radioresistance is the intrinsic dependence of RT on oxygen to 
cause damage to the tumour cell. For damage to be inflicted on tumour cells 
by ionizing radiation, the presence of oxygen is necessary because it mediates 
DNA damage through formation of free radicals by interaction of ionizing 
radiation with intracellular water. Hypoxia has also been shown to reduce 
chemotherapeutic efficacy by causing cells within hypoxic regions to cycle 
more slowly and by providing a selection mechanism for cells with reduced 
susceptibility for apoptosis. Additionally, due to limited drug penetration 
within solid tumours, hypoxic regions are often protected from the cytotoxic 
effects of chemotherapeutic agents further reducing drug efficacy.  
All these mechanisms together ensure that tumour hypoxia is a negative 
prognostic factor. In order to predict outcome and identify patients with a 
worse prognosis and/or patients that would benefit from appropriate 
treatments, in vivo measurement of tumour hypoxia is required. 
A variety of invasive and noninvasive approaches have been developed to 
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3.1.1 Invasive measurement of tumour hypoxia 
At present, the gold standard for direct in vivo determination of tumour 
oxygenation is a commercially available oxygen electrode, commonly referred 
to as the Eppendorf electrode. 
However, this technically demanding procedure has a number of drawbacks 
and limitations like its sensitivity for sampling errors, its invasive nature and 
the fact that only easily accessible tumours can be studied (e.g., those in the 
oral cavity). In addition, a system that allows the tracking of the electrode 
during measurements has not been developed. 




3.1.2 Non-invasive measurement of tumour hypoxia 
These techniques use various labels that can be detected by different 
methods such as positron emission tomography (PET), single photon emission 
computed tomography (SPECT), magnetic resonance imaging (MRI), 
autoradiography and immunohistochemistry. Moreover, in the detection of 
tumour hypoxia the most encouraging results have been obtained using 
radiotracers that selectively accumulate in hypoxic tumours and which can be 
applied together with functional PET or SPECT imaging
106
. 
SPECT is similar to PET in its use of radioactive tracer material and detection 
of gamma rays. In contrast with PET, however, the tracer used in SPECT 
emits gamma radiation that is measured directly, whereas PET tracer emits 
positrons which annihilate with electrons up to a few millimetres away, 
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Figure 3.3: Schema of a pet acquisition process. 
 
There are several prerequisites to which the ideal non-invasive hypoxic marker 
should comply:  
1. It should be specific for hypoxia and thus distinguish normoxia, 
hypoxia and anoxia or necrosis.  
2. It should image acute and chronic hypoxia and possibly distinguish 
between both. 
3. It should be simple, non-toxic, fast, easy to perform and allow repeated 
measurements.  
4. It should be lipophilic to have a homogeneous biodistribution in all 
tissues including tumours but at the same time hydrophilic to have a 
faster elimination, thus allowing larger tumour to normal tissue ratio of 
radioactivity.  
5. It should have little hypoxia-independent degradation in vivo leading to 
non-specific tracer metabolites and/or little aspecific tissue binding, so 
that only oxygen-specific retention mechanisms determine the amount 
of tracer that is temporarily or permanently trapped.  
6. It should reflect intracellular pO2 rather than blood flow or some 
consequence of subsequent biochemistry. 
7. It should be sensitive at pO2 levels relevant to tumour therapy.  
8. It should offer the ability to quantify. 
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Unfortunately, none of the present hypoxia tracers available completely fulfils 
these requirements. 
Although SPECT is more commonly used than PET, and, in particular, it
 
has a 
number of practical advantages that include ready availability at low cost, and 
versatile chemistry, the superior spatial resolution and more accurate 
quantitation with PET makes the latter a better candidate for detection of 
tumoural hypoxia. In addition, radiation exposure of normal tissues is less due 





Fluorine-18, a radioactive isotope of fluorine first produced by Snell is 
currently the positron-emitting radioisotope of choice for the development of 
radiopharmaceuticals for positron emission tomography (PET), one of the 
most powerful nuclear medicine imaging technique in man. Reasons for such 
an interest for fluorine-18 are related to the physical and nuclear properties of 
this radioisotope: its half-life (109 min), its positron decay (97%) and positron 
weak energy (635 keV maximum, 2.3 mm range in matter), are particularly 
advantageous in term of resolution and dosimetry. During the last years, a 
significant number of articles have reported the use of fluorine-18 for the 
synthesis of new labelled tracers and their in vivo studies, in particular in man 
as illustrated by the wide clinical use in oncology of: [
18









 [18F]FDG (2-deoxy-2-[18F]fluoro-D-glucose) 
In PET imaging, 
18
F-FDG (Fig. 3.4) can be used for the assessment of 
glucose metabolism in the heart, lungs, and the brain. [
18
F]FDG-PET is a non-
invasive functional imaging method that is routinely used for cancer detection, 
staging and monitoring of response in several tumour types. Most cancer cells 
have increased glycolysis rates, accompanied by overexpression of glucose 
transmembrane transporters (GLUTs) and hexokinases (HKs) compared to 
normal cells. GLUTs assist in transporting glucose into the cell. Cellular 
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glucose becomes phosphorylated by HKs resulting in its retention inside the 
cell. 
18
F-FDG is taken up by cells, phosphorylated by hexokinase (whose 
mitochondrial form is greatly elevated in rapidly-growing malignant tumours), 
and retained by tissues with high metabolic activity, such as most types of 
malignant tumours. As a result FDG-PET can be used for diagnosis, staging, 
and monitoring treatment of cancers, particularly in Hodgkin's disease, non-
Hodgkin's lymphoma, colorectal cancer, breast cancer, melanoma, and lung 









Figure 3.4: Structure of 18FDG. 
 
FDG, as a glucose analog, is taken up by high-glucose-using cells such as 
brain, kidney, and cancer cells, where phosphorylation prevents the glucose 
from being released again from the cell, once it has been absorbed. The 2' 
hydroxyl group (—OH) in normal glucose is needed for further glycolysis 
(metabolism of glucose by splitting it), but FDG is missing this 2' hydroxyl. 
Thus, in common with its sister molecule 2-deoxy-D-glucose, FDG cannot be 
further metabolized in cells. The 
18
F-FDG-6-phosphate formed when 
18
F-FDG 
enters the cell thus cannot move out of the cell before radioactive decay. As a 
result, the distribution of 
18
F-FDG is a good reflection of the distribution of 
glucose uptake and phosphorylation by cells in the body. 
After 
18




, and after picking up a proton H
+
 from a hydronium ion in its aqueous 
environment, the molecule becomes glucose-6-phosphate labeled with 
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harmless nonradioactive "heavy oxygen" in the hydroxyl at the 2' position. 
The new presence of a 2' hydroxyl now allows it to be metabolized normally 
in the same way as ordinary glucose, producing non-radioactive end-products. 
Because the uptake of [
18
F]FDG during FDG PET imaging relies largely on 
the expression of proteins that are under control of HIF-1, the degree of 
[
18
F]FDG uptake by tumours might indirectly reflect the level of hypoxia. 
Reports trying to relate [
18
F]FDG uptake with tumour hypoxia have, however, 
given inconsistent results. In vitro studies have suggested that FDG should be 
accumulated in hypoxic cancer cells compared to normoxic cancer cells 
because of changed metabolism. However, in vivo experiments (pre-clinical 
and clinical) have given conflicting results when showing a correlation 
between the uptake of [
18
F]FDG and the existence of hypoxia in tumours
103
. 
PET imaging of [
18
F]FDG will highlight all zones presenting a variation of the 
glucidic metabolism, in particular in tumours whose energetic metabolism is 
exacerbated at time of proliferation. [
18
F]FDG is not however the universal 
tumour marker and there are limitations to its effectiveness for cancer studies, 





 Nitroimidazole compounds 
One promising non-invasive approach to assess hypoxia is to utilize 
appropriately-labelled radiosensitizers which will bind to oxygen-deficient 
tissues, but not to normally-oxygenated tissues. Selective binding of reactive 
reduction intermediates of nitroimidazole radiopharmaceuticals to the 
macromolecular fraction of hypoxic tissues has been porstulated to be the 
basis for concentrating these compounds in target (hypoxic) tissues.  
These compounds are reduced into reactive intermediary metabolites by 
intracellular reductases in a process which is directly related to the level of 
oxygenation/hypoxia. This causes a gradient which is favourable for detection 
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of hypoxic cells. In particular, 2-Nitroimidazoles can undergo a series of 
oxygen-reversible single-electron reductions in hypoxic environments, 
forming reactive oxygen radicals
103
.  
The nitro-radical anion produced in the first reduction step is very reactive 
toward oxygen, leaving no substrate for the second step of the reduction 
process. In contrast, an environment of low oxygen concentration induces 
further reductive reactions that ultimately lead to the formation of either 
reactive products that are able to covalently bind to cell components or 
charged species that diffuse slowly out of the tissues. The reactive products 
observed during this multi-step process include nitroso (2e-), hydroxylamine 
(4e-), and amine (6e-) derivatives. When the fragmentation of the imidazole 
ring occurs, reactive portions of the molecule, such as glyoxal, bind to 
macromolecular components of cells in tissues and tumors. 
In particular, metabolites obtained covalently bind to thiol groups of 
intracellular proteins and thereby accumulate within viable hypoxic cells.  
When labelled with a PET tracer, these chemicals can be detected using PET 
imaging methods.  
The ideal nuclear medicine marker should have a partition coefficient 
(lipid/water solubility) which promotes rapid and nearly equal distribution to 
body tissues so that the quantity of marker which becomes bound to cells, 
especially in tumors, will be an approximate inverse image of intracellular 
oxygen concentration.  
Several nitroimidazole compounds with different properties and labelled with 
different PET radionuclides have been described, in particular two have 
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F]FMISO (Fig. 3.5) is the most widely used and investigated hypoxia 
marker and has been validated in multiple studies both in humans and animals. 
Studies using [
18
F]FMISO have demonstrated variable, but significant levels 
of hypoxia in several tumour types.  
In addition, [
18
F]FMISO PET imaging has been used as a prognostic indicator 






Figure 3.5: Structure of [18F]FMISO.  
 
In a number of studies, [
18
F]FMISO uptake was compared with [
18
F]FDG 
uptake. Most of these studies demonstrated the feasibility and utility of 
[
18
F]FMISO PET imaging to identify tumour hypoxia, whereas [
18
F]FDG PET 
imaging seemed less suitable for this purpose. A number of studies compared 
[
18
F]FMISO uptake with invasive Eppendorf electrode pO2 measurements. In 
some of these studies, [
18
F]FMISO uptake in renal cell carcinoma and head 
and neck cancer correlated well with pO2 measurements from polarographic 
needle oxygen electrodes, confirming the use of [
18
F]FMISO PET to measure 
tumour hypoxia. 




F]FMISO in patients 
with head and neck cancer. They found no correlation between [
18
F]FDG 
uptake and pO2 measurements, whereas an association between [
18
F]FMISO 
uptake and pO2 measurements existed. Further comparison of [
18
F]FDG and 
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F]FMISO indicated that no correlation exists between both tracers as both 
represent different tumour characteristics. 
It has, however, failed to gain wider acceptance for routine clinical application 
because of a number of limitations such as: (1) slow accumulation in hypoxic 
tumours; (2) a low target to background ratio due to high non-specific binding 
resulting from its relatively high lipophilicity; and (3) significant non-oxygen 




However, the utility of 
18
FMISO is limited by the fact that one has to wait 
several hours after tracer application for clearance from the normoxic 
background tissue. This is a major deficiency, given the short half-life of 
radioisotope (110 min). In addition, clearance via the hepatobiliary and 
intestinal systems adds to the radiation dose to the patient, when compared to 
renally cleared tracers.  
It therefore warrants the development of a more hydrophilic congener of 
18
FMISO that overcomes these limitations without compromising its 












The optimal hypoxia-selective reductive binding potential and faster 
clearance properties of several radioiodinated sugar-coupled 2-
nitroimidazoles, in comparison to non-sugared azomycins, led to their clinical 
advancement as imaging radiodiagnostics. Exploitation of the shorter half-life 
of F-18 (110 min) and the superior image resolution of PET formed the basis 
to develop 
18
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F]-FAZA (Fig. 3.6) is currently being used in several tumor hypoxia based 
clinical diagnostic studies. Radiolabeled FAZA, radiodiagnostic used 
extensively in the nuclear medicine community, is C-5‘ substituted azomycin 
nucleosides; it has free hydroxyl groups at C-2‘ and C-3‘, a strongly electron-
withdrawing nitro group at the C-5 imidazole position and the fluorine atom in 



















F-FAZA) was invented and developed at the Cross Cancer 
Institute (Edmonton, Alberta). It is a 2-nitroimidazole-based molecule that 
undergoes reductive metabolism under hypoxic conditions, forming highly 
reactive intermediates that consequently bind to macromolecular cellular 
components.  
Preclinical studies have shown that 
18
F-FAZA is rapidly cleared from the 
circulation and nonhypoxic tissues, and is excreted mainly via the renal 
pathway, thereby providing more favourable tumour-tobackground (T/B), 
tumour-muscle (T/M) and tumour-blood (T/B) ratios in most anatomical 
regions. Moreover, its faster clearance from the body results in shorter waiting 
times after tracer application and perhaps a lower radiation exposure. In 
contrast, 
18
F-FMISO, that is more lipophilic agent, is cleared primarily through 
the hepatobiliary route and undergoes nonspecific lipoidal uptake in the brain, 
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liver and other organs, thereby interfering with the image quality in the region 
of interest.  
The in vitro as well as the in vivo experiments indicated that 
18
F-FAZA is an 
excellent marker for tumour hypoxia, whereas 
18
F-FDG is not. 
Given the potential advantages of 
18
F-FAZA for imaging hypoxia, a phase I/II 
study was performed to demonstrate the safety of the 
18
F-FAZA drug product 
manufactured jointly by the Edmonton PET Centre and the Edmonton 
Radiopharmaceutical Centre, and to determine the general biodistribution 
pattern of this PER in patients with HNSCC, small-cell lung cancer (SCLC) or 
non-small-cell lung cancer (NSCLC), malignant lymphoma, or high-grade 
gliomas (astrocytoma and glioblastoma multiforme), GBM. 
This study suggested that 
18
F-FAZA may be a very useful radiopharmaceutical 
to image hypoxia in the tumour types selected. Especially the high uptake by 
gliomas was encouraging. Given the good imaging properties, including 
acceptable T/B ratios in the tumour categories studied, 
18
F-FAZA could be 





F-FAZA is a PET radiotracer that is currently being used in human cancer 
patients in several cancer hospitals to develop improved treatment plans by 
assessing the presence of hypoxia in solid tumors and correlate the hypoxia 
levels with the treatment response. 
18
F-FAZA has been indicated to be a 
superior clinical agent due to its superior central compartment clearance in 
comparison to 
18
F-FMISO and is clinically being studied to see the 
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3.2 Synthesis of [18F]FAZA 
 
 As mentioned above, the aim of my Ph.D. visiting period was to perform 
the synthesis of the 
18
F-FAZA precursor with the view of introducing 
18
F-
FAZA as a hypoxia radiotracer in Scotland. Unfortunately, the current method 
to synthesise FAZA is not very efficient. 
Original synthetic pathway for FAZA is uneconomical and lengthy since it 
involves expensive reagents, and a multi-step process that requires several 
days of reaction, purification of the intermediate products. This lowers the 
overall chemical yield of FAZA (~12%) and results in tremendous time and 
reagents‘ loss
113
. In addition, this synthesis is not particularly well detailed in 
the literature. Therefore, after a careful bibliography research on 
18
F-FAZA 
synthesis and its subsequent optimization, the Scheme 1 was used for the 
synthesis of 1-α-D-[5’-O-Toluenesulfonyl-2’,3’-Di-Oacetylarabinofuranosyl]-












Scheme 1. Synthesis of 18F-FAZA. Reagents and conditions: (a) hexamethyldisilazane 
(HMDS), ammonium sulfate, reflux, 4h; (b) mercuric cyanide, anhydrous acetonitrile, 
50°C, 16h, 40%; (c) NH3 in CH3OH, 10 h at 0°C, all weekend at rt, 90%; (d) 4-Tosyl 
chloride, anhydrous pyridine over KOH, 5°C, 48h, 60%; (e) acetic anhydride, , 
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In Scheme 1 2-nitroimidazole (Azomicin, 1) was treated with 
Hexamethyldisilazane (HMDS) and a catalytic amount of ammonium sulfate 
to give its N-1-trimethylsilyl derivative (2). After removal of HMDS excess 
under complete exclusion of moisture and under high vacuum, compound 2 
was subjected to a stereoselective mercuric cyanide-assisted coupling with the 
respective bromosugar (3) to afford 1-(α-D-2,3,5-Tri-O-
benzoylarabinofuranosyl)-2-nitroimidazole (α-tribenzoyl AZA, 4)
114
. The 
formation of the nucleoside product 4 was confirmed by comparison of its 
physical and spectroscopic data with those reported in the literature. 
In this reaction, interaction of the protective group at C-2‘ hydroxyl plays a 
significant role in determining the final conformation of the coupled base. 
In theory, nucleophilc substitution should occur with the inversion of 
configuration but by coupling of 1-α-bromo-2,3,5-tri-O-benzoyl 
arabinofuranose with 1-trimethylsilyl-2-nitroimidazole resulted in the 
exclusive formation of α-coupled product as expected according to the trans 
rule (double Walden inversion), whereby the benzoyl carbonyl group in the 2‘-
ara configuration facilitates this mechanism. In particular, intramolecular 
involvement of the β-plane electrons with electropositive C-1 creates steric 
hindrance to nucleophilic approach of 2-nitroimidazole from the α-face and 
results in the exclusive formation of α-azomycin tribenzoylarabinofuranoside 
(α-Tribenzoyl AZA). Moreover, the use of benzyl-or substituted silyl-(non-
carbonylated) groups instead of benzoyl protective groups avoids this retention 
of configuration. 
Subsequently, a deprotection of compound 4 was performed in the presence of 
NH3/methanol (2M solution) and α-AZA (5) was obtained. For this step, the 
originally described procedure was modified
115
. In fact, according to the 
standard method, we obtained mainly the 1-(2-benzoyl-α-D-arabinofuranosyl)-
2-nitroimidazole (monobenzoyl AZA, Fig. 3.7) and only a few milligrams of 
AZA (21% of yield). 
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Figure 3.7: Structure of monobenzoyl AZA. 
 
To increase the yield of this step of reaction, a variation of some parameters 
was made (Table 3.1), in particular: volume of NH3/Methanol 2M solution 


















Method mL NH3/MeOH  
(for 0.054 mmol of 4) 




4  10h 6h 21 
B 6 10h 24h 50 
C 6 10h 50h 90 
Table 3.1: Tested methods of deprotection. 
 
The optimal conditions identified by means of these trials are outlined in the 
method C. Then, the application of this method on compound 4 led to the 
synthesis of compound 5 in 90% yield. 
A subsequent tosylation by combining the alcohol 5 with 4-toluenesulfonyl 
chloride in an aprotic solvent, such as pyridine, afforded 1-α-D-[5‘-O-
Toluenesulfonyl-arabinofuranosyl-2-nitroimidazole (Ts-AZA, 6). 
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Using the condition showed in literature, the product Ts-AZA was obtained in 
a very low yield (8%) because the starting material 5 did not react. 
Therefore, several trials were made for identifying the optimal conditions for 
the formation of compound 6. 
The validation of tosylation was performed in a rigorous manner in which the 
variation of different parameters was considered: stoichiometry of reagents, 
catalyst, distillation of solvent, reaction time and temperature. The different 
















5 6  











1 1.4 / Dry 4 -10 8 
B 1 1 DMAP




C 1 1 / 
dried over 
KOH 
42 5 27 
D 1.5 1 / 
dried over 
KOH 
42 5 60 
Table 3.2: Tested methods of tosylation.  
 
The best conditions were therefore identified (method D): 4-Tosyl chloride 
(1.5 equiv.) was added to a precooled (5°C) solution of AZA (1.0 equiv.) in 
anhydrous pyridine (dried over KOH). The temperature was maintained to 
5°C, and the reaction was complete in nearly 42h, affording Ts-AZA (6) in 
60% yield. 
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Finally, we synthesized DAcTsAZA (7) via acetylation with acetic anhydride, 




H-NMR and Mass characterization 




To perform clinical studies with [
18
F]FAZA, the optimal synthesis conditions 
in a labeling procedure with good yields and high reproducibility, will be 
performed in the John Mallard Scottish PET centre at the Aberdeen Royal 








F]Fluoride will be produced at the PETtrace cyclotron by 
irradiation of enriched [
18




F nuclear reaction.  
Then, the synthesis of 1-(5-[18F]fluoro-5-deoxy-a-D-arabinofuranosyl)-2-
nitroimidazole ([
18
F]FAZA) will take place by nucleophilic substitution and 





























1. [K / 2.2.2.]18F, DMSO
2. NaOH
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The procedure will be performed by means of an automated, commercially 
available module (Fig. 3.9) for highly reliable production of [
18
F]FAZA in 
amounts sufficient for clinical studies. As showed in literature, the automated 
synthesis affords 
18
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The present work was divided into several sections. In the early years the 
known broad-spectrum antiviral properties of Arbidol, led us to focus on its 
derivatives as potential antiviral agents. Therefore, we designed and 
synthesized several novel ethyl 1H-indole-3-carboxylate derivatives, using 
ARB as lead compound. In order to maintain antiviral activity we preserved 
the groups responsible of Arbidol interaction with membranes, eliminated 
those that were not considered pharmacophores (hydroxy and bromo groups at 
the 5- and 6-positions of the indole ring) and introduced different building 
blocks in 2- and 5-position. On this basis two synthetic schemes were 
validated: the Scheme 1 can be used for the synthesis of derivatives with 
different amine scaffolds in 5-position; the Scheme 6 can be used for the 
synthesis of derivatives with different substituents in 2-position. Biological 
assays on first compounds 9a1–6 and 9b1–2, against Hepatitis C virus (HCV) 
genotype 2a and  Herpes simplex type 1, demonstrated that ARB derivatives 
have anti-HCV and anti-HSV activity comparable to and, in some cases, even 
better than those of lead Arbidol. In particular, it was demonstrated that 
synthesized compounds are fusion inhibitors on both viruses and also 
inhibitors of HCV replication. Furthermore, it was also shown that all 
synthesized compounds are not selective inhibitors of HCV replication 
(genotype 1b, Con1 strain). 
Subsequently, the attention was focused to study the mechanism of Arbidol 
anti-influenza action and the interaction of ARB with the N-terminal 
hydrophobic fusion domain of Haemagglutinin (HA, a surface viral protein of 
influenza virus) was evaluated. Therefore, the peptide host-guest (P20H6) was 
synthesized using techniques of Solid Phase Peptide Synthesis (SPPS) and 
Circular dichroism studies were made. From these studies we demonstrated 
that Arbidol interacts with the haemagglutinin fusion domain at pH5 and 7, 
through changes in the secondary structure of peptide. In addition, the 
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prominent interaction was at fusiogenic pH in which we had a transition from 
α-helix to β sheet with increasing of ARB concentration.  
At the end of my Ph.D. project, I spent six months at the University of 
Aberdeen where I worked to the synthesis of a PET (Positron Emission 
Tomography) radiotracer for tumour hypoxia: the [
18
F]1-α-D-(5-Fluoro-5-





currently the gold standard for PET Imaging of diseases characterized by 
hypoxia (solid tumours, ischemia, stroke), but it is not routinely used and 
synthesized in Scotland. The work done is an important starting point for the 
introduction of 
18
F-FAZA in Scotland with the aim of using it in clinical 
imaging and research. In particular, the 
18
F-FAZA precursor was synthesized: 
1-α-D-[5’-O-Toluenesulfonyl-2’,3’-Di-Oacetylarabinofuranosyl]-2- nitro 
imidazole (DAcTs-AZA). This precursor will be used for the radiochemical 
synthesis of 
18
F-FAZA in the J. Mallard Scottish PET Centre at the University 
of Aberdeen.  
Currently, in regard to Arbidol derivatives tests are in progress to evaluate 
anti-HCV and anti-HSV activity of last synthesized compounds 9(c-d)1-2 and 
9e1. Moreover, to evaluate the antiviral spectrum of synthesized compounds 
against other viruses (influenza virus, HBV, etc) and to assess whether these 
compounds, such as Arbidol, interact with the N-terminal fusion hydrophobic 
domain of Haemagglutinin (HA, surface protein of influenza virus), circular 
dichroism studies and other biological assays will be performed.  
The positive biological results obtained and the new results will be the basis 
for a rational study of a second series of compounds that will analyze in a 
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4.1 CHEMISTRY 
4.1.1 Material and methods 
Synthesis in solution of Arbidol derivatives and reaction intermediates. 
Microwave experiments were performed in a CEM Discover monomode 
reactor (CEM Corp., Matthews, NC). All reactions were conducted in a 
specially adapted cylindrical Pyrex vessel. All reagents were analytical grade 
and purchased from Sigma–Aldrich (Milano, Italy). Flash chromatography 
was performed on Carlo Erba silica gel 60 (230–400 mesh; Carlo Erba, Milan, 
Italy). TLC was carried out using plates coated with silica gel 60F 254 nm 
purchased from Merck (Darmstadt, Germany). Melting points were 
determined in open capillary tubes on an Electrothermal 9100 apparatus and 
are uncorrected. 
1
H NMR spectra were registered on a Bruker AC 300. 
Chemical shifts are reported in ppm. All target compounds were assessed for 
purity by analytical high performance liquid chromatography (HPLC) using an 
Agilent 1100 series instrument equipped with a UV detector monitoring at 254 
nm, HP Chem Station software, and a Waters C18 RP-column (5 µm, 300 mm 
x 3.9 mm). All target compounds were found to have >95% purity. 
Mass spectra (MS) were taken in ESI mode on a Finnigan LCQ Deca ion trap 
instrument. Microanalyses were carried out on a Carlo Erba 1106 elemental 






-Fmoc-protected natural amino acids, Rink-amide resin, 
HBTU, DCC, HOBt were purchased from Fluka–Sigma–Aldrich (Milan, 
Italy). Peptide synthesis solvents and reagents and CH3CN for HPLC were 
reagent grade and were purchased from Riedel–Sigma–Aldrich (Milan, Italy) 
and used without further purification. 
Peptide was synthesized according to the solid-phase approach using standard 
Fmoc methodology in a manual reaction vessel. 
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Peptide was purified with (RP-HPLC) using a Phenomenex, Jupiter C-18 
(250x4,60 mm, 5 μm, 300 Å) column and a concentration gradient of 
CH3CN/H2O with 0.1% of TFA (flow rate 2 ml/min). Molecular weight was 
determined with a Finnigan™ LCQ™ Deca electrospray ionization/ion trap 
mass spectrometer. 
Synthesis in solution of 18-FAZA precursor and reaction intermediates. All 
reagents were analytical grade and purchased from Sigma–Aldrich (UK). 2-
Nitroimidazole was purchased from Merck (UK). Flash chromatography was 
performed on silica gel Geduran® Si 60 (0.040-0,0630) mesh (Merck UK). 
TLC was carried out using glass plates coated with silica gel 60F 254 nm 




C NMR spectra were registered on a 
Varian 400-MR. Mass spectra (MS) were taken in ESI mode on Thermo 
Surveyor TSQ Quantum. LC-MS analysis were performed on an Agilent 1200 
LC-MS system. 
 
4.1.2 General procedure for the synthesis of compounds 3d-e 
The sodium salt of ethyl acetoacetate  (20 mmol) was dissolved in THF (40 
mL) distilled and cooled to 0 °C, and n-butyllithium (2.0 M in cyclohexane, 
21.0 mmol) was added dropwise. After 30 min 2-phenylbenzyl bromide 2d or 
farnesyl bromide 2e (10 mmol) was added to the solution of dianion and 
stirring was continued for 30 min at 0 °C. The mixture was then poured into a 
cold saturated solution of potassium hydrogen phosphate and extracted with 
ether. The combined organic layers were washed with water, dried over 
Na2SO4, filtered, and concentrated. The residue was purified by flash 
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4.1.2.1 Ethyl 3-oxo-5-((2-phenyl)phenyl) pentanoate (3d). Slightly yellow oil 
(90%); 
1
H NMR (CDCl3): δ 1.29 (t, J = 7.1 Hz, 3H, -OCH2CH3); 2.68 (t, 2H, -
COCH2CH2-); 2.93 (t, 2H, -COCH2CH2-); 3.31 (s, 2H, -CO-CH2-CO-); 4.12 
(q, J=7.2 Hz, 2H, -OCH2CH3); 7.14-7.48 (m, 9H, -PhH-PhH ). 
 
4.1.2.2 Ethyl 7,11,15-trimethyl-3-oxohexadeca-6,10,14-trienoate (3e). 
Slightly yellow oil (81%); 
1
H NMR (CDCl3): δ 1.29 (t, J = 7.1 Hz, 3H, -
OCH2CH3); 1.61 (m, 9H, -CH3 farnesyl) 1.71 (s, 3H, -CH3 farnesyl); 2 (m, 8H, 
CH2 farnesyl); 2.32 (q, 2H, -CH2CH2CO-); 2.62 (t, 2H, -CH2-CH2-CO-); 3.41 
(s, 2H, -CO-CH2-CO); 4.2 (q, J=7.2 Hz, 2H, -OCH2CH3); 5.1 (m, 3H, =CH-). 
 
4.1.3 General procedure for the synthesis of compounds 5b–d 
A mixture of 4-bromo-2-iodoaniline (20 mmol), ethyl acetoacetate 3b or 3-
oxo-4 (phenylthio)butanoate 3c or ethyl 3-oxo-5-((2-phenyl)phenyl) 
pentanoate 3d (22 mmol), CuI (2 mmol), BINOL (4 mmol) and Cs2CO3 (20 
mmol) in DMSO (35 ml) was stirred at 50 °C for 5–7 h under an atmosphere 
of nitrogen. After this time, the mixture was partitioned between ethyl acetate 
and saturated NH4Cl. The organic layer was washed with brine, dried over 
sodium sulphate and concentrated in vacuo. The residue was purified by flash 
chromatography over silica gel to give 5b-d. 
 
4.1.3.1 Ethyl 5-bromo-2-methyl-1H-indole-3-carboxylate (5b). Elution with 
toluene/EtOAc (95:5) afforded 5b (52%) as gray-green powder; mp: 163–165 
°C; 
1
H NMR (CDCl3): δ 1.5 (t, J = 7.2 Hz, 3H, –OCH2CH3); 2.75 (s, 3H, –
CH3); 4.45 (q, J = 7.2 Hz, 2H, –OCH2CH3); 7.2 (d, 1H, –ΦH); 7.35 (dd, J = 
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4.1.3.2     Ethyl 5-bromo-2-((phenylthio)methyl)-1H-indole-3-carboxylate 
(5c). Elution with n-hexane/EtOAc (95:5) afforded 5c (56%) as yellow 
powder; mp: 142–144 °C; 
1
H NMR (CDCl3): δ 1.47 (t, J = 7.2 Hz, 3H, –
OCH2CH3); 4.42 (q, J = 7.2 Hz, 2H, –OCH2CH3); 4.80 (s, 2H, –CH2-sulfonyl–
); 7.18 (d, 1H, –ΦH); 7.20–7.5 (m, 6H, –ΦH and –PhH); 8.20 (s, 1H, –ΦH); 




4.1.3.3   Ethyl 5-bromo-2-((phenylphenyl)ethyl)-1H-indole-3-carboxylate 
(5d). Elution with benzene/chloroform (7:3) afforded 5d (48%) as white 
powder; 
1
H NMR (CDCl3): δ 1.5 (t, J = 7.1 Hz, 3H, -OCH2CH3); 3.08 (t, 2H, -
CH2CH2-Ph-Ph); 3.25 (t, 2H, -CH2CH2-Ph-Ph); 4.40 (q, J = 7.2 Hz, 2H, -
OCH2CH3); 7.05 (d, 1H, -ΦH); 7.20-7.5 (m, 10H, -PhH–PhH and -ΦH); 8.20 




4.1.4 General procedure for the synthesis of compounds 6b-d 
To a stirred solution of compound 5b or 5c or 5d (9 mmol) in DMF (40 
mL) at 0 °C was added freshly powdered potassium hydroxide (10 mmol). 
After stirring the mixture for 30 min at 0 °C, methyl iodide (13.5 mmol) was 
added dropwise with vigorous stirring. After 1 h, the reaction mixture was 
diluted with diethyl ether and washed with saturated NaCl solution. The 
organic layer was dried (Na2SO4), and the solvent was removed in vacuo to 
yield 6b-d. 
 
4.1.4.1 Ethyl 5-bromo-1,2-dimethyl-1H-indole-3-carboxylate (6b).  Brown 
powder (92%); mp: 98–100 °C; 
1
H NMR (CDCl3): δ 1.5 (t, J = 7.2 Hz, 3H, –
OCH2CH3); 2.83 (s, 3H, –CH3); 3.77 (s, 3H, –NCH3); 4.45 (q, J = 7.2 Hz, 2H, 
–OCH2CH3); 7.2 (d, 1H, –ΦH); 7.35 (dd, J = 8.55, 1.75 Hz, 1H, –ΦH); 8.28 (s, 
1H, –ΦH); MS: m/z 296.1, 298.1 [MH+].  
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4.1.4.2       Ethyl 5-bromo-1-methyl-2-((phenylthio)methyl)-1H-indole-3- 
carboxylate (6c). White powder (97%); mp: 109–111 °C; 
1
H NMR (CDCl3): δ 
1.45 (t, J = 7.2 Hz, 3H, –OCH2CH3); 3.70 (s, 3H, –NCH3); 4.35 (q, J = 7.2 Hz, 
2H, –OCH2CH3); 4.78 (s, 2H, –CH2-sulfonyl–); 7.18 (d, 1H, –ΦH); 7.20–7.5 
(m, 6H, –ΦH and –PhH); 8.23 (s, 1H, –ΦH); MS: m/z 404.0, 406.0 [MH+]. 
 
4.1.4.3       Ethyl 5-bromo-1-methyl-2-((phenylphenyl)ethyl)-1H-indole-3-
carboxylate (6d). White powder (87%); 
1
H NMR (CDCl3): δ 1.5 (t, J = 7.1 Hz, 
3H, -OCH2CH3); 3.0 (s, 3H, -N-CH3); 3.08 (t, 2H, -CH2CH2-Ph-Ph); 3.25 (t, 
2H, -CH2CH2-Ph-Ph); 4.40 (q, J = 7.2 Hz, 2H, -OCH2CH3); 7.05 (d, 1H, -





4.1.5 General procedure for the synthesis of compounds 7b-d 
A solution of potassium vinyltrifluoroborate (8 mmol), PdCl2 (0.2 mmol), 
PPh3 (0.6 mmol), Cs2CO3 (9.6 mmol), and compound 6b or 6c or 6d (3.2 
mmol) in THF/H2O (9:1) (24 mL) was heated at 85 °C and stirred for 20–22 
h. Then, the reaction mixture was cooled to room temperature and diluted with 
H2O, followed by extraction with dichloromethane. The solvent was removed 
in vacuo, and the crude product was purified by silica gel chromatography to 
give compounds 7b-d. 
 
4.1.5.1 Ethyl 1,2-dimethyl-5-vinyl-1H-indole-3-carboxylate (7b). Elution with 
n-hexane/ EtOAc (9:1) afforded 7b (92%) as yellow powder; mp: 51–53 °C; 
1
H NMR (CDCl3): δ 1.5 (t, J = 7.2 Hz, 3H, –OCH2CH3); 2.83 (s, 3H, –CH3); 
3.77 (s, 3H, –NCH3); 4.45 (q, J = 7.2 Hz, 2H, –OCH2CH3); 5.23 (d, J = 11.18 
Hz, 1H, CH2=CH–); 5.7 (d, J = 17.54, 1H, CH2=CH–); 6.87 (dd, J = 17.10, 
10.74 Hz, 1H, CH2=CH–); 7.25 (d, 1H, –ΦH); 7.45 (dd, J = 8.55, 1.75 Hz, 1H, 
–ΦH); 8.20 (s, 1H, –ΦH); MS: m/z 244.0 [MH+]. 
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4.1.5.2        Ethyl 1-methyl-2-((phenylthio)methyl)-5-vinyl-1H-indole-3-
carboxylate (7c). Elution with n-hexane/ EtOAc (9:1) afforded 7c (97%) as 
yellow powder; mp: 103–105 °C; 
1
H NMR (CDCl3): δ 1.42 (t, J = 7.2 Hz, 3H, 
–OCH2CH3); 3.70 (s, 3H, –NCH3); 4.35 (q, J = 7.2 Hz, 2H, –OCH2CH3); 4.78 
(s, 2H, –CH2-sulfonyl–); 5.23 (d, J = 10.96 Hz, 1H, CH2=CH–); 5.7 (d, J = 
11.54 Hz, 1H, CH2=CH–); 6.87 (dd, J = 17.87, 10.74 Hz, 1H, CH2=CH–); 7.25 





4.1.5.3       Ethyl 1-methyl-2-((phenylphenyl)ethyl)-5-vinyl-1H-indole-3-
carboxylate (7d). Elution with toluene/petroleum ether (9:1) afforded 7d 
(90%) as white powder; 
1
H NMR (CDCl3): δ 1.5 (t, J = 7.1 Hz, 3H, -
OCH2CH3); 3.0 (s, 3H, -N-CH3); 3.08 (t, 2H, -CH2CH2-Ph-Ph); 3.25 (t, 2H, -
CH2CH2-Ph-Ph); 4.40 (q, J = 7.2 Hz, 2H, -OCH2CH3); 5.20 (d, 1H, CH2=CH-
); 5.78 (d, 1H, CH2=CH-); 6.87 (dd, 1H, CH2=CH-); 7.05 (d, 1H, -ФH); 7.20-




4.1.6 General procedure for the synthesis of compounds 8(a,b,d) 
OsO4 (0.1 mmol) was added to a stirred mixture of 7b or 7c (1 mmol) and 
2,6-lutidine (2 mmol) in dioxane (26 mL). The mixture turned from colorless 
to black in 1 min. Sodium periodate (4 mmol) in water (6 mL, warmed to 
dissolve) was added. A gray precipitate was immediately formed. The mixture 
was stirred for 20 min, then extracted with water and dichloromethane. The 
organic layers were combined, dried, filtered and concentrated. The residue 
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4.1.6.1    Ethyl 5-formyl-1-methyl-2-((phenylsulfonyl)methyl)-1H-indole-3-
carboxylate (8a). Elution with n-hexane/ EtOAc (7:3) afforded 8a (95%) as 
gray-white powder; mp: 136–138 °C; 
1
H NMR (CDCl3): δ 1.3 (t, J = 7.2 Hz, 
3H, –OCH2CH3); 4.03 (s, 3H, –NCH3); 4.15 (q, J = 7.2 Hz, 2H, –OCH2CH3); 
5.33 (s, 2H, –CH2-sulfonyl–); 7.45–7.75 (m, 6H, –ΦH and –PhH); 7.95 (d, 1H, 




4.1.6.2   Ethyl 5-formyl-1,2-dimethyl-1H-indole-3-carboxylate (8b). Elution 
with n-hexane/ EtOAc (7:3) afforded 8b (92%) as beige powder; mp: 118–120 
°C; 
1
H NMR (CDCl3): δ 1.5 (t, J = 7.2 Hz, 3H, –OCH2CH3); 2.83 (s, 3H, –
CH3); 3.77 (s, 3H, –NCH3); 4.45 (q, J = 7.2 Hz, 2H, –OCH2CH3); 7.45 (d, 1H, 
–ΦH); 7.88 (dd, J = 8.55, 1.75 Hz, 1H, –ΦH); 8.67 (s, 1H, –ΦH); 10.12 (s, 1H, 




4.1.6.3      Ethyl 5-formyl-1-methyl-2-((phenylphenyl)ethyl)-1H-indole-3-
carboxylate (8d). Elution with dichloromethane/petroleum ether (7:3) afforded 
8d (90%) as white powder; 
1
H NMR (CDCl3): δ 1.5 (t, J = 7.1 Hz, 3H, -
OCH2CH3); 3.0 (s, 3H, -N-CH3); 3.08 (t, 2H, -CH2CH2-Ph-Ph); 3.25 (t, 2H, -
CH2CH2-Ph-Ph); 4.40 (q, J = 7.2 Hz, 2H, -OCH2CH3); 7.45 (d, 1H, -ФH); 
7.75-7.9 (m, 10H, -PhH–PhH and –ФH); 8.67 (s, 1H, -ФH); 10.12 (s, 1H, -




4.1.7 General procedure for the synthesis of compounds 8c 
K3Fe(CN)6 (25 mmol), K2CO3 (25mmol) and OsO4 (0.83 mmol) were 
added to a solution of 7c (8.3 mmol) in dioxane /water (1:1; 120 mL). After 30 
min. Pb(OAc)4 (33.3 mmol) was added to the reaction and stirred all night at 
room temperature. The reaction was quenched by the addition of solid Na2SO3 
and saturated NaHSO3, and extracted with ethyl acetate. The combined 
organic extracts were washed with brine, dried over Na2SO4 and concentrated 
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and purified by flash chromatography (petroleum ether/ethyl acetate, 9.1) to 
provide 8c (53%) as white solid. 
1
H NMR (CDCl3): δ 
1
H NMR (CDCl3): δ 1.3 (t, J = 7.2 Hz, 3H, –OCH2CH3); 
3.71 (s, 3H, –NCH3); 4.3 (q, J = 7.2 Hz, 2H, –OCH2CH3); 4.72 (s, 2H, –CH2-
sulfur–); 7.39–7.65 (m, 6H, –ΦH and –PhH); 7.75 (d, 1H, –ΦH); 8.12 (s, 1H, –




4.1.8 General procedure for the synthesis of compounds 9a1–2 
Compound 8a (0.04 g, 0.1 mmol), dimethylamine or pyrrolidine (0.12 
mmol), acetic acid (0.06 mL, 1.02 mmol) and NaB(OAc)3H (0.05 g, 0.21 
mmol) were, in that order, added to dry THF (4 mL). The mixture was 
irradiated with microwaves for 10 min at 130 °C. Additional amine (0.12 mol) 
and NaB(OAc)3H (0.05 g, 0.21 mmol) were added, and the mixture was 
irradiated at 130 °C for 5 min. This gave 100% conversion to product. The 
reaction mixture was filtered and concentrated. The residue was dissolved in 
methanol (1.5 mL) and concd HCl (0.5 mL) and irradiated using microwaves 
at 100 °C for 5 min. The mixture was filtered and purified by flash 
chromatography over silica gel (benzene/methanol, 9:1) to give the desired 
compounds 9a1–2. 
 
4.1.8.1            Ethyl 5-((dimethylamino)methyl)-1-methyl-2-((phenyl 
sulfonyl)methyl)-1H-indole-3-carboxylate (9a1). Sandy powder (0.033 g, 
78%); mp: 205–208 °C; 
1
H NMR (CDCl3): δ 1.45 (t, J = 7.2 Hz, 3H, –
OCH2CH3); 2.45 (s, 6H, –N(CH3)2); 3.82 (s, 2H, –CH2N<); 3.95 (s, 3H, –
NCH3); 4.05 (q, J = 7.2 Hz, 2H, –OCH2CH3); 5.25 (s, 2H, –CH2-sulfonyl–); 
7.3–7.75 (m, 7H, –ΦH and –PhH); 8.0 (s, 1H, –ΦH); MS: m/z 415.0 [MH+]. 
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4.1.8.2 Ethyl 1-methyl-2-((phenylsulfonyl)methyl)-5-((pyrrolidin-1yl) 
methyl)-1H-indole-3-carboxylate (9a2). Beige powder (0.039 g, 87%); mp: 
118–120 °C; 
1
H NMR (CDCl3): δ 1.3 (t, J = 7.2 Hz, 3H, –OCH2CH3); 1.87 (s, 
4H, –pyrrolidinyl H); 2.73 (s, 4H, –pyrrolidinyl H); 3.82 (s, 2H, –CH2N<); 
3.95 (s, 3H, –NCH3); 4.05 (q, J = 7.2 Hz, 2H, –OCH2CH3); 5.25 (s, 2H, –CH2-





4.1.9 Synthesis of N-Boc homopiperazine 13 
To a solution of dichloromethane (45 mL) and homopiperazine 11 (1.84 g, 
18 mmol), maintained at 0 °C using an ice bath, was added dropwise a di-tert-
butyldicarbonate solution 12 (2 g, 9 mmol in 18 mL dichloromethane). The 
mixture was stirred for an additional 1 h then was filtered.  
The filtrate was concentrated to dryness. Water (27 mL) was added to the 
resulting oil, and the mixture was filtered. The filtrate was saturated with 
potassium carbonate and extracted with diethyl ether (3 x 13 mL). The solvent 
was dried over sodium sulfate and concentrated to dryness, yielding 13 (1.58 
g, 88%). 
 
4.1.10 General procedure for the synthesis of compounds 9a3–5 
Compound 8a (0.04 g, 0.1 mmol), 4-methylpiperazine or morpholine or 1-
BOC-homopiperazine (0.15 mmol), acetic acid (0.06 mL, 1.02 mmol) and 
NaB(OAc)3H (0.055 g, 0.24 mmol) were, in that order, added to dry THF (4 
mL). The mixture was irradiated with microwaves for 10 min at 130 °C. 
Additional amine (0.15 mol) and NaB(OAc)3H (0.055 g, 0.24 mmol) were 
added, and the mixture was irradiated at 130 °C for 5 min. This gave 100% 
conversion to product. The reaction mixture was filtered and concentrated. 
The residue was dissolved in methanol (1.5 mL) and conc. HCl (0.5 mL) and 
irradiated using microwaves at 100 °C for 5 min. The mixture was filtered and 
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((phenylsulfonyl)methyl)-1H-indole-3-carboxylate (9a3). Elution with 
benzene/MeOH (9:1) afforded 9a3 (0.045 g, 94%) as a brownish-yellow 
powder; mp: 94–96 °C; 
1
H NMR (CDCl3): δ 1.3 (t, J = 7.2 Hz, 3H, –
OCH2CH3); 2.57 (s, 3H, 4-CH3 of piperazinyl); 2.75–3.05 (m, 8H, 8H of 
piperazinyl); 3.75 (s, 2H, –CH2N<); 3.95 (s, 3H, –NCH3); 4.05 (q, J = 7.2 Hz, 
2H, –OCH2CH3); 5.25 (s, 2H, –CH2-sulfonyl–); 7.3–7.7 (m, 7H, –ΦH and –




4.1.10.2 Ethyl 1-methyl-5-(morpholinomethyl)-2-((phenylsulfonyl) 
methyl)-1H-indole-3-carboxylate (9a4). Elution with benzene/MeOH (95:5) 
afforded 9a4 (0.039 g, 85%) as an rose powder; mp: 109–111 °C; 
1
H NMR 
(CDCl3): δ 1.3 (t, J = 7.2 Hz, 3H, –OCH2CH3); 2.53 (s, 4H, 4H of 
morpholino); 3.65 (s, 2H, –CH2N<); 3.75 (s, 4H, 4H of morpholino); 3.95 (s, 
3H, –NCH3); 4.05 (q, J = 7.2 Hz, 2H, –OCH2CH3); 5.25 (s, 2H, –CH2-





4.1.10.3 Ethyl 5-((1,4-diazepan-1yl)methyl)-1-methyl-2-((phenyl 
sulfonyl) methyl)-1H-indole-3-carboxylate (9a5). Elution with 
benzene/MeOH/NH4OH (9:1:0.25) afforded 9a5 (0.04 g, 83%) as a white 
powder; mp: 98–100 °C; 
1
H NMR (CD3OD): δ 1.3 (t, J = 7.2 Hz, 3H, –
OCH2CH3); 2.0 (s, 1H, –NH of homopiperazine); 2.1 (m, 2H, 2H of 
homopiperazine); 2.95 (t, 2H, 2H of homopiperazine); 3.1 (t, 2H, 2H of 
homopiperazine); 3.35 (t, 4H, 4H of homopiperazine); 3.90 (s, 3H, –NCH3); 
4.0 (s, 2H, –CH2N<); 4.15 (q, J = 7.2 Hz, 2H, –OCH2CH3); 5.4 (s, 2H, –CH2-
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4.1.11 Synthesis of ethyl 5-(hydroxymethyl)-1-methyl-2-((phenylsulfonyl) 
methyl)-1H-indole-3-carboxylate (10a) 
To an ice-cooled solution of the corresponding aldehyde 8a (0.12 g, 0.3 
mmol) in THF (1.5 mL) was added NaBH4 (0.029 g, 0.75 mmol) in methanol 
(3.8 mL). Then, the resulting mixture was stirred at rt for 1 h. After complete 
conversion, the solvent was distilled off under reduced pressure. Then, water 
was added, and the resulting mixture was extracted with ethyl acetate. The 
combined organic phases were washed with brine, dried over Na2SO4 and 
evaporated under reduced pressure. The desired product was purified by 
chromatography on silica gel (hexane/EtOAc 6:4) to give 10a (0.106 g, 91%) 
as white solid; mp: 172–174 °C; 
1
H NMR (CDCl3): δ 1.3 (t, J = 7.2 Hz, 3H, –
OCH2CH3); 2.0 (s, 1H, –CH2OH); 3.97 (s, 3H, –NCH3); 4.05 (q, J = 7.2 Hz, 
2H, –OCH2CH3); 4.82 (s, 2H, –CH2-sulfonyl–); 5.28 (s, 2H, –CH2OH); 7.4–




4.1.12 Synthesis of ethyl 5-((1H-imidazol-1-yl)methyl)-1-methyl-2-
((phenyl sulfonyl)methyl)-1H-indole-3-carboxylate (9a6) 
To a solution of compound 10a (0.06 g, 0.15 mmol) in acetonitrile (1.5 mL) 
was added CDI (0.127 g, 0.75 mmol) and imidazole (0.021 g, 0.3 mmol). The 
resulting solution was heated to reflux for 16 h. After cooling to ambient 
temperature, the reaction mixture was diluted with water and extracted with 
ethyl acetate. The combined organic phases were washed with brine, dried 
over Na2SO4 and evaporated under reduced pressure. The desired product was 
purified by chromatography on silica gel (dichloromethane/methanol, 98:2) to 
obtain 9a6 (0.044 g, 67%) as a pearl-white powder; mp: 95–97 °C; 
1
H NMR 
(CDCl3): δ 1.3 (t, J = 7.2 Hz, 3H, –OCH2CH3); 3.97 (s, 3H, –NCH3); 4.05 (q, J 
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= 7.2 Hz, 2H, –OCH2CH3); 5.28 (s, 4H, –CH2-sulfonyl– and –CH2N<); 6.95 
(s, 1H, 2-1H of imidazolyl) 7.05–7.2 (m, 2H, 4,5-2H of imidazolyl); 7.4–7.75 




4.1.13 General procedure for the synthesis of compounds 9b1–2 
Compound 8b (0.04 g, 0.1 mmol), dimethylamine or pyrrolidine (0.12 
mmol), acetic acid (0.095 mL, 1.02 mmol) and NaB(OAc)3H (0.074 g, 0.21 
mmol) were, in that order, added to dry THF (4 mL). The mixture was 
irradiated with microwaves for 10 min at 130 °C. Additional amine (0.12 
mmol) and NaB(OAc)3H (0.074 g, 0.21 mmol) were added, and the mixture 
was irradiated at 130 °C for 5 min. This gave 100% conversion to product. 
The reaction mixture was filtered and concentrated. The residue was  
dissolved in methanol (1.5 mL) and conc. HCl (0.5 mL) and irradiated using 
microwaves at 100 °C for 5 min. The mixture was filtered and purified by 
flash chromatography over silica gel (benzene/methanol, 95:5) to give the 
desired compounds 9b1–2. 
 
4.1.13.1 Ethyl 5-((dimethylamino)methyl)-1,2-(dimethyl)-1H-indole-3-
carboxylate (9b1). Bone powder (0.033 g, 75%); mp: 67–69 °C; 
1
H NMR 
(CDCl3): δ 1.45 (t, J = 7.2 Hz, 3H, –OCH2CH3); 2.65 (s, 6H, –N(CH3)2); 2.83 
(s, 3H, –CH3); 3.77 (s, 3H, –NCH3); 4.30 (s, 2H, –CH2–N<); 4.45 (q, J = 7.2 
Hz, 2H, –OCH2CH3); 7.45 (d, 1H, –ΦH); 7.60 (dd, J = 8.55, 1.75 Hz, 1H, –





carboxylate (9b2). Nut-brown powder (0.04 g, 83%); mp: 125–127 °C; 
1
H 
NMR (CDCl3): δ 1.45 (t, J = 7.2 Hz, 3H, –OCH2CH3); 1.59 (m, 4H, –
pyrrolidinyl H); 2.25 (m, 4H, –pyrrolidinyl H); 2.83 (s, 3H, –CH3); 3.77 (s, 
3H, –NCH3); 4.30 (s, 2H, –CH2– N<); 4.45 (q, J = 7.2 Hz, 2H, –OCH2CH3); 
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7.45 (d, 1H, –ΦH); 7.78 (dd, J = 8.55, 1.75 Hz, 1H, –ΦH); 8.15 (s, 1H, –ΦH); 




4.1.14 General procedure for the synthesis of compounds 9c1–2 
Compound 8c (0.04 g, 0.12 mmol), dimethylamine or pyrrolidine (0.14 
mmol), acetic acid (0.074 mL, 1.2 mmol) and NaB(OAc)3H (0.055 g, 0.25 
mmol) were, in that order, added to dry THF (4 mL). The mixture was 
irradiated with microwaves for 10 min at 130 °C. Additional amine (0.12 
mmol) and NaB(OAc)3H (0.055 g, 0.25 mmol) were added, and the mixture 
was irradiated at 130 °C for 5 min. This gave 100% conversion to product. 
The reaction mixture was filtered and concentrated. The residue was  
dissolved in methanol (1.5 mL) and conc. HCl (0.5 mL) and irradiated using 
microwaves at 100 °C for 5 min. The mixture was filtered and purified by 
flash chromatography over silica gel (dichloromethane/methanol, 9:1) to give 
the desired compounds 9c1–2. 
 
4.1.14.1 Ethyl 5-((dimethylamino)methyl)-1-methyl-2-((phenyltio) 
methyl)-1H-indole-3-carboxylate (9c1). White powder (0.032 g, 82%); mp: 
1
H 
NMR (CDCl3): δ 1.39 (t, J = 7.2 Hz, 3H, –OCH2CH3); 2.76 (s, 6H, –N(CH3)2); 
3.71 (s, 2H, –CH2N<); 3.72 (s, 3H, –NCH3); 4.31 (q, J = 7.2 Hz, 2H, –
OCH2CH3); 4.74 (s, 2H, –CH2-sulfur–); 7.3–7.67 (m, 6H, –ΦH and –PhH); 
7.75 (d, 1H, –ΦH); 8.12 (s, 1H, –ΦH); MS: m/z 383.0 [MH+]. 
 
4.1.14.2 Ethyl 1-methyl-2-((phenyltio)methyl)-5-((pyrrolidin-
1yl)methyl)-1H-indole-3-carboxylate (9c2). Brown powder (0.035 g, 84%); 
mp: 
1
H NMR (CDCl3): δ 1.39 (t, J = 7.2 Hz, 3H, –OCH2CH3); 1.9 (s, 4H, –
pyrrolidinyl H); 2.2 (s, 4H, –pyrrolidinyl H); 3.70 (s, 3H, –NCH3); 3.81 (s, 2H, 
–CH2N<); 4.31 (q, J = 7.2 Hz, 2H, –OCH2CH3); 4.74 (s, 2H, –CH2-sulfur–); 
7.3–7.69 (m, 7H, –ΦH and –PhH); 8.08 (s, 1H, –ΦH); MS: m/z 409.0 [MH
+
]. 
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4.1.15 General procedure for the synthesis of compounds 9d1–2 
Compound 8d (0.042 g, 0.1 mmol), dimethylamine or pyrrolidine (0.15 
mmol), acetic acid (0.060 mL, 1 mmol) and NaB(OAc)3H (0.055 g, 0.24 
mmol) were, in that order, added to dry THF (4 mL). The mixture was 
irradiated with microwaves for 10 min at 130 °C. Additional amine (0.15 
mmol) and NaB(OAc)3H (0.055 g, 0.24 mmol) were added, and the mixture 
was irradiated at 130 °C for 5 min. This gave 100% conversion to product. 
The reaction mixture was filtered and concentrated. The residue was  
dissolved in methanol (1.5 mL) and conc. HCl (0.5 mL) and irradiated using 
microwaves at 100 °C for 5 min. The mixture was filtered and purified by 
flash chromatography over silica gel (toluene/methanol, 9:1) to give the 
desired compounds 9d1–2. 
 
4.1.15.1 Ethyl 5-((dimethylamino)methyl)-1-methyl-2-((phenyl phenyl) 
ethyl) -1H-indole-3-carboxylate (9d1). Yellow oil (0.035 g, 78%); mp: 
1
H 
NMR (CDCl3): δ 1.45 (t, J = 7.1 Hz, 3H, -OCH2CH3); 2.35 (s, 6H, -N(CH3)2); 
3.0 (s, 5H, -N-CH3 and -CH2-N(CH3)2); 3.24 (t, 2H, -CH2CH2-Ph-Ph); 3.6 (t, 
2H, -CH2CH2-Ph-Ph); 4.45 (q, J = 7.2 Hz, 2H, -OCH2CH3); 7.1-7.6 (m, 11H, -




4.1.15.2 Ethyl 1-methyl-2-((phenylphenyl)ethyl)-5-((pyrrolidin-1yl) 
methyl)-1H-indole-3-carboxylate (9d2). Yellow powder (0.036 g, 75%); mp: 
1
H NMR (CDCl3): δ 1.45 (t, J = 7.1 Hz, 3H, -OCH2CH3); 1.85 (m, 4H, - 
pyrrolidinyl H); 2.15 (m, 4H, - pyrrolidinyl H); 2.85 (t, 2H, -CH2CH2-Ph-Ph); 
3.08 (s, 3H, -N-CH3); 3.2 (t, 2H, CH2CH2-Ph-Ph); 4.25 (s, 2H, -CH2-N<); 4.45 
(q, J = 7.2 Hz, 2H, -OCH2CH3); 7.2-7.4 (m, 11H, -PhH–PhH e –ФH); 8.08 (s, 
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4.1.16 Synthesis of 4-amino-3-iodobenzoic acid (14) 
Ethyl-4-aminobenzoate (47 mmol) was dissolved in 100 ml mixture of 
AcOH:H2O (9:1). NaIO4 (47 mmol), NaCl (93 mmol) and KI (47 mmol) were 
added sequentially. The reaction mixture was stirred at room temperature over 
night, then diluted with EtOAc and washed with brine, then with a saturated 
solution of Na2O3S2 and finally, with a saturated solution of NaHCO3. The 
organic layer was dried over Na2SO4, the solvent removed under reduced 
pressure, and the crude product purified by column chromatography on silica 
gel (EtOAc:Hex 1:9) to give compound 14 (70%) as a yellow powder. 
1
H 
NMR (CDCl3): δ 4.61 (s, 2H, NH2); 6.75 (d, J=8.4Hz, 1H, -ФH); 7.87 (dd, 
J3=8.4Hz, 1H,  ФH); 8.38 (s, 1H, -ФH). 
 
4.1.17 Synthesis of 4-amino-3-iodophenyl)methanol (15) 
A solution of compound 14 (25 mmol) in 10 mL of diethyl ether was added 
dropwise to a suspension of dry diethyl ether (60ml) and lithium aluminum 
hydride (30 mmol) under nitrogen and cooled to 0°C. The mixture is stirred 
for 16 hr at room temperature and cooled again to 0°C. The mixture is 
carefully worked up by the dropwise and sequential addition of 1.1 mL of 
water, 1.1 mL of a 15% aqueous sodium hydroxide solution and an additional 
3.4 mL of water. The reaction mixture is filtered through a coarse filtration frit 
to remove aluminum salts, and the latter are washed four times with 8-mL 
portions of diethyl ether . The combined filtrates and washings are dried over 
sodium sulphate and concentrated under reduced pressure to give compound 
15 (81%) as a yellow powder. 
1
H NMR (CDCl3): δ 3.22 (s, 2H, -NH2); 4.55 (s, 
2H, CH2OH); 6.75 (d, J=8.6Hz, 1H, -ФH); 7.18 (dd, J3=8.4Hz, 1H, -ФH); 7.67 
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4.1.18 Synthesis of 4-amino-3-iodobenzaldehyde (16) 
PDC (56.66 mmol) and 360 ml of anhydrous dichloromethane were added 
to a flask. The resulting suspension was stirred at room temperature and under 
nitrogen atmosphere for 40 minutes. Then, alcohol 15 was added, and  the 
reaction mixture was stirred for 2 h. Upon completion of the oxidation as 
indicated by TLC, the reaction mixture was filtered and evaporated under 
vacuum. The crude product was purified by column chromatography on silica 
gel (EtOAc:Hex 3:7) to give compound 16 (80%) as a yellow powder. 
1
H 
NMR (CDCl3): δ 4.7 (s, 1H, -NH2); 6.81 (d, J=8.6Hz, 1H, -ФH); 7.68 (dd, 
J3=8.4Hz, 1H, -ФH); 8.12 (s, 1H, -ФH); 9.7 (s, 1H, -CHO). 
 
4.1.19 Synthesis of N-(4-formyl-2-iodophenyl)acetamide (17) 
Freshly distilled acetic anhydride (60.0 mmol) was added to a solution of 
compound 16 (2.0 mmol) in methylene chloride (28 ml). After the mixture 
was stirred for 30 h at rt, than it was concentred and purified by flash column 
chromatography on silica gel (EtOAc:Hex 2:8) to give compound 17 (87%) as 
a yellow powder. 
1
H NMR (CDCl3): δ 2.38 (s, 3H, -COCH3); 7.78 (s, 1H, -
NH-); 7.93 (dd, J3=8.4Hz, 1H, -ФH); 8.38 (s, 1H, -ФH); 8.57 (d, J=8.6Hz, 1H, 
-ФH); 9.91 (s, 1H, -CHO). 
 
4.1.20 Synthesis of N-(4-formyl-2-iodophenyl)-N-methylacetamide (18) 
A solution of compound 17 (2.08 mmol) in freshly distilled THF (7 ml) was 
added dropwise to a suspension of 60% NaH in mineral oil (2.28 mmol) in 
THF (3 ml) under nitrogen and cooled to 0°C. The reaction was agitated and 
maintained at 0°C until it became clear (about 30 min) and a solution of CH3I 
(2.7 mmol) in THF (3 ml) was dripped. The reaction was brought to rt and 
kept under nitrogen and stirring for 3h. To the reaction was diluted with H2O 
and extracted with EtOAc. The organic phases were anidrificate with sodium 
sulfate and the solvent removed. The compound 18 (yield 75%) was obtained 
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by crystallization in hexane. 
1
H NMR (CDCl3): δ 1.85 (s, 3H, -COCH3); 3.2 
(s, 3H, -NCH3); 7.45 (d, J=8.6Hz, 1H, -ФH); 7.95 (dd, J3=8.4Hz, 1H, -ФH); 
8.42 (s, 1H, -ФH); 10.0 (s, 1H, -CHO). 
 
4.1.21 Synthesis of N-(2-iodo-4-((pyrrolidin-1-yl)methyl)phenyl)-N-
methylacetamide (19) 
Compound 18 (1.541 mmol), dimethylamine or pyrrolidine (1.849 mmol), 
acetic acid (0.9 mL, 15.76 mmol) and NaB(OAc)3H (3.2 mmol) were, in that 
order, added to dry THF (7 mL). The mixture was irradiated with microwaves 
for 10 min at 130 °C. The mixture was filtered and purified by flash 
chromatography over silica gel (dichloromethane/methanol, 95:5) to give the 
desired compounds 19 (85%). 
1
H NMR (CDCl3): δ 1.85 (m, 4H, - pyrrolidinyl 
H); 2.2 (s, 3H, -COCH3); 2.7 (m, 4H, - pyrrolidinyl H); 3.2 (s, 3H, -NCH3); 
3.75 (s, 2H, -CH2-N<); 7.3 (d, J=8.4Hz, 1H, -ФH); (dd, J3=8.4Hz, 1H, -ФH); 




4.1.22 Synthesis of 2-iodo-N-methyl-4-((pyrrolidin-1-yl)methyl) 
benzenamine (20) 
A mixture of 19 (3.12 mmol) and NaOH (156 mmol) in ethanol (125 ml) 
and water (30 ml) was heated to reflux with stirring for 20 h. The mixture was 
cooled and the solvent was removed under vacuum. The residue was 
partitioned between chloroform and water. The organic phase was washed 
with water, dried (Na2SO4), and evaporated under vacuum to give compound 
20 (91%), as a brown oil. 
1
H NMR (CDCl3): δ 1.85 (m, 4H, - pyrrolidinyl H); 
2.2 (s, 3H, -COCH3); 2.7 (m, 4H, - pyrrolidinyl H); 3.2 (s, 3H, -NHCH3); 3.75 
(s, 2H, -CH2-N<); 4.0 (s, 1H, -NH-); 6.31 (d, J=8.6Hz, 1H, -ФH); 7.08 (dd, 
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4.1.23 Synthesis of Ethyl 1-methyl-2-(-4,8,12-trimethyltrideca-3,7,11-
trienyl)-5-((pyrrolidin-1yl)methyl)-1H-indole-3-carboxylate (9e1). 
A mixture of compound 20 (0.068 g, 0.215 mmol), compound 3e (0.145 g, 
0.430 mmol), CuI (0.008 g, 0.043 mmol), BINOL (0.025 g, 0.086 mmol) and 
Cs2CO3 (0.142, 0.43 mmol) in DMSO (1 mL) was stirred at 50 °C for 7 h 
under an atmosphere of nitrogen. After this time, the mixture was partitioned 
between ethyl acetate and saturated NH4Cl. The organic layer was washed 
with brine, dried over sodium sulfate and concentrated in vacuo. The residue 
was purified by flash chromatography (THF/Acetone 9:1) over silica gel to 
give 9e1 (0.049g, 45%). 
1
H NMR (CDCl3): 1.29 (t, J = 7.1 Hz, 3H, -
OCH2CH3); 1.59 (m, 4H, -pyrrolidinyl H); 1.61 (m, 9H, -CH3 farnesyl) 1.71 
(s, 3H, -CH3 farnesyl); 2 (m, 8H, CH2 farnesyl); 2.32 (q, 2H, -CH2-CH2-Ф); 
2.62 (t, 2H, -CH2-CH2-Ф); 3.62 (s, 5H, -CH2-N< and -NCH3); 4.3 (q, J=7.2 
Hz, 2H, -OCH2CH3); 5.1 (m, 3H, =CH-); 6.7 (d, J=8.6Hz, 1H, -ФH); 7.3 (dd, 




4.1.24 Synthesis of host-guest peptide (P20H10) 
The synthesis of peptide was performed manually in a stepwise fashion by 
the solid-phase Fmoc/tBu method. First amino acid N

Fmoc-Lys-(BOC)-OH 
(4eq), was coupled to 0.149 g of Rink-amide resin (with a degree of 
substitution of 0.5 mmol / g),  The following protected amino acids (4 eq) 
were then added stepwise according to established sequence. Each coupling 
reaction was accomplished through the use of a four-fold amino acid molar 
excess with activation with an equimolar excess of HBTU (or DCC) and 
HOBt in the presence of DIPEA (8 eq) for 2h. The peptide resin was washed 
with DMF (2x), and DCM (2x), and the completeness of the coupling reaction 
was checked by the Kaiser test. The N
α
-Fmoc protecting groups were removed 
after each coupling cycle by treatment of the protected peptide resin with 
piperidine in DMF (30%) for 15 min. The N-terminal Fmoc group was 
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removed as described above, and the peptide was released from the resin with 
TFA/H2O/TIPS (90:5:5, v/v/v) for 3 h. The resin was removed by filtration, 
and the crude peptide was recovered by precipitation with cold ethyl ether to 
give a white powder. Finally the crude peptide was purified by RP-HPLC on a 
C18-bonded silica column (Phenomenex-Jupiter, 0.46 cm x25 cm) using a 
gradient of 0.1% TFA in CH3CN at a flow rate of 2.0 mL/ min. The final 
product was obtained by lyophilization of the appropriate fractions after 
removal of the CH3CN by rotary evaporation. Preparative RP-HPLC was 
carried out on  Shimadzu system. Analytical RP-HPLC indicated a purity 
>98%. Molecular masses were determined on a Finnigan LCQ-Deca ion trap 
instrument fitted with an electrospray source (San Jose, CA) and molecular 
weights were confirmed by ESI mass spectrometry (ESI-MS: 2681.06). 
 
4.1.25 Synthesis of 1-(Tri-O-benzoyl-α-D-arabinofuranosyl)-2-nitro 
imidazole (Tribenzoyl-AZA; 4) 
The bromosugar 3 (0.71 mmol), described above, was dissolved in 
anhydrous acetonitrile (40 mL) and added to the flask containing 1-N-
trimethylsilyl-2-nitroimidazole 2 (0.868 mmol). This was followed by the 
addition of mercuric cyanide (1.562 mmol), after which the reaction flask was 
filled with nitrogen. The reaction mixture was heated at 50°C for 16 h. TLC 
examination at this time showed complete conversion of the bromosugar 3 to 
the azomycin nucleoside 4. The solvent was evaporated on a rotary evaporator, 
the residue was dissolved in CH2Cl2, and then washed sequentially with 30% 
w:v aqueous potassium iodide and then cold water. The dichloromethane 
phase was dried over anhydrous sodium sulfate, filtered, evaporated and 
purified on a silica gel column (Hexane/EtOAc 7:3) to yield 4 (40%) as a 




C NMR spectra for 4 was 
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4.1.26 Synthesis of 1-(α-D-arabinofuranosyl)-2-nitroimidazole (α-AZA; 5) 
To 4 (0.054 mmol) was added a solution of NH3 in CH3OH (6 mL of 2M 
solution) at 0°C under nitrogen and the resulting solution was stirred 10 h at 
0°C and 50 h at room temperature. The solvent was then removed under 
vacuum (rotovap). Purification of the residue via flash column 
chromatography on silica gel (CH2Cl2/CH3OH 9:1) gave 5 (90%) as white 




C NMR spectra for 5 and  1-(2-benzoyl-α-




4.1.27 Synthesis of 1-α-D-(5’-O-Toluensulfonyl-arabinofuranosyl)-2-
nitroimidazole (Ts-AZA; 6) 
Compound 5 (AZA, 0.571 mmol) was dissolved in anhydrous pyridine (2 
mL, dried over KOH), the solution was cooled at 5°C,  and tosyl chloride 
(0.856 mmol) was added to it under stirring. The reaction mixture was stirred 
at that temperature for 42 h, then quenched by adding few pieces of ice. The 
solvent was removed and the residual viscous material was purified on a silica 
gel column using MeOH/CH2Cl2 (3:97, v/v) as eluent to afford 6 (60%). The 









4.1.28 Synthesis of 1-α-D-(5’-O-Toluensulfonyl-2’,3’-Di-O-acetylarabino 
furanosyl)-2-nitroimidazole (DAcTs-AZA; 7) 
Acetic anhydride (0.75 ml) was added to a solution of 6 (400 mg, 1 mmol) 
and the mixture was stirred overnight at room temperature. The reaction was 
quenched by addition of water (1 ml) to the reaction mixture. The solvent was 
removed by evaporation on a rotavapor and the impure mixture was purified 
on a silica gel column using CH2Cl2:MeOH (97:3, v/v) as eluent to afford 
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4.2 Biological assays 
4.2.1. Anti-HCV assay 
4.2.1.1 Cell lines and culture conditions 
The human hepatoma-derived cell line Huh-7.5 was grown in high-glucose 
Dulbecco‘s modified Eagles‘ medium (DMEM; Life Technologies) 
supplemented with 2 mM L-glutamine, 100 U/mL of penicillin, 100 µg/mL of 
streptomycin, and 10% fetal bovine serum.
123
 Cells were sub-cultivated twice 
per week, with a 1:4 split ratio. 
 
4.2.1.2 In vitro anti-HCV assay  
The antiviral activities of compounds 9a1–5, 9b1–2 against HCV were 
measured in Huh-7.5 hepatoma cells using replication and entry assays as 
previously described by Pacini et al.
124
 For the replication assay, an RNA 
transcript of a replicon containing a firefly luciferase reporter was transfected 
in Huh-7.5 cells; these were subsequently plated on 96-well plates in the 
presence of test compounds and Arbidol. For the infection assay, viral 
particles containing a subgenomic HCV RNA carrying a firefly luciferase 
reporter gene were used to infect naive Huh-7.5 cells; these were plated in a 
96-well format in the presence of test compounds and Arbidol. After three 
days of incubation luciferase activity was measured with a Bright-Glo 
luciferase assay system (Promega) following the manufacturer‘s instructions. 
The EC50 and SI of the evaluated compounds and Arbidol were calculated. 
 
4.2.1.3.  Cytotoxicity assay 
Cytotoxicity induced by the test compounds in cultures of cells was also 
determined. The toxicity of compounds 9a1–5 and 9b1–2 in Huh-7.5 cells was 
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evaluated by CellTiter-Blue Viability Assay (Promega) that is used to estimate 
the number of viable cells present in multiwall plates; the reagent is a buffered 
solution containing highly purified resazuin. Resazuin is dark blue in color and 
has little intrinsic fluorescence. Metabolically active cells can reduce resazuin 
to resorufin, which is pink and highly fluorescent, with an excitation 
maximum of 579 nm and an emission maximum of 584 nm. Nonviable cells 
rapidly lose metabolic capacity, do not reduce the indicator dye, and thus do 
not generate a fluorescent signal. 
 
4.2.1.3 In vitro selective anti-HCV activity 
The selective antiviral activity of compounds 9a1–5, 9(b-d)1–2 against HCV 
replication was measured in the Huh 5-2 HCV replicon system (type 1b, Con1 
strain), as  described previously.
125 
 
4.2.2. Anti-HSV assay  
4.2.2.1  Virus preparation 
HSV-1 strain HF obtained from ATCC (American Type Culture Collection) 
was grown and titred in VERO cells. To produce the virus amount necessary 
for the experiments, the cells were incubated in RPMI medium supplemented 
with 2mM glutamine, 100 U/ml penicillin, 0.1mg/ml streptomycin and 2% 
heat inactivated FCS in a 75 cm
2
 flask, and then rinsed with serum-free 
medium and infected with HSV 1 at a low multiplicity of infection (MOI) of 
0.001 plaque-forming units (PFU)/cell. One hour post-infection (p.i.) at 37 °C, 
15–20ml of RPMI with 2% FCS was added and the cells were cultured for 
about 3 days. Seventy two hours after virus challenge culture supernatants 
were harvested after three cycles of cells freezing (-80 °C)/defrosting, they 
were clarified by centrifugation at 800 g for 10min, titred and stored in small 
volumes at -80 °C. A virus stock solution containing approximately 10
9
 
PFU/ml was used in all the experiments. 
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4.2.2.2  Plaque assay 
To choose the best concentration of Arbidol and its analogues to test for the 
antiviral activity, a preliminary plaque assay was performed. Briefly confluent 
monolayers of HaCat cells were treated with Arbidol, 9b2, 9b1 and 9a2 at 
different concentration (12, 6, 3 and 1 M) for 3 h. As positive control we use 
a treatment with acyclovir 10M. The cells were then washed with PBS and 
infected with HSV-1 at MOI of 0.001 PFU/ cell. After 1 h of incubation at 37 
°C (adsorption period), the unadsorbed virus was removed and the monolayers 
were incubated for an additional 72 h in DMEM medium (supplemented with 
2% FCS) with carboxymethyl cellulose (CMC) (ratio 1:1). After incubation 
period the cells were fixed and stained with 1% crystal violet dissolved in a 
10% formalin solution, the plaques were scored and the plaque number 
calculated based on the mean count of three replicate wells. The toxic effect of 
the concentrations of Arbidol and its analogues used, 12μM, 6μM, 3μM and 
1μM were tested on keratinocytes in preliminary dose–response experiments, 
all the concentration tested did not alter cell viability. 
 
4.2.2.3  Assays for antiviral activity 
In order to identify which phase of HSV-1 replication 
(preadsorption/adsorption or post-adsorption period) was affected by Arbidol 
and its analogues, three sets of experiments were performed. 
1. The confluent monolayers of HaCat cells were pretreated with Arbidol, 
9b2, 9b1 and 9a2  3 M for 3 h. After the incubation, the medium was 
removed and the cells were infected at MOI of 5 PFU/cell in presence 
or not of the stimuli. After the adsorption period, the virus was 
removed and fresh medium at 2% FCS was added. The supernatants 
were collected after 24 and 48 h.  
2. The confluent monolayers of HaCat were infected at MOI of 5 
PFU/cell at the same time Arbidol, 9b2, 9b1 and 9a2 3 M were added. 
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After the adsorption period, the virus was removed and fresh medium 
at 2% FCS was added. The supernatants were collected after 24, 48h.  
3. The confluent monolayers of HaCat were infected at MOI of 5 
PFU/cell. After the adsorption period, the virus was removed and fresh 
medium at 2% FCS with stimuli was added. The supernatants were 
collected after 24 and 48 h.  
The supernatant were harvested and tested for their ability to form plaques in 
the HaCat cells using a standard titration method. Briefly, serial-fold dilutions 




) were made and 100 μl of each dilution 
was added to the cell monolayers seeded in 12-well multiwells. After 1 h of 
adsorption, the medium was removed and fresh DMEM containing 2% FCS 
with carboxymethyl cellulose (CMC) (ratio 1:1) was added. After 72 h of 
incubation, the cells were fixed and stained with 1% crystal violet dissolved in 
a 10% formalin solution. The plaques were counted and the plaque number 
was calculated based on the mean count of three replicate wells. 
 
4.3 Circular dichroism studies 
Circular dichroism (CD) experiments were performed at 25°C on a 810-
Jasco spectropolarimeter using a quartz cuvette with a path length of 1 mm, a 
bandwidth of 0.1 nm, a time constant of 2.0 s and a wavelength range of 190-
260 nm in 0.2-nm steps. The far-UV CD spectra were performed on peptide in 
H2O at 200 µΜ concentration, at pH 5 and 7, in lysophosphatidylcholine 
micelles (LPC), with or without Arbidol. The spectrum of the buffer was 
subtracted from all the other spectra; the results of 4 scans were then averaged. 
In addition, the estimation of the secondary structure composition was carried 
out using the algorithm K2D by DichroWeb.  
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CC50 50% cytotoxic concentration 
CD Circular dichroism 
CD3OD Deuterated methanol 
CDCl3 Deuterated chloroform 
CH2Cl2 Dichloromethane 
CH3CN Acetonitrile 
CH3COOH Acetic acid 
CH3I Methyl iodide 
CH3OH Methanol 
CMV Cytomegalovirus 
Cs2CO3 Cesium carbonate 






DMSO Dimethyl Sulfoxide 
EBV Epstein-Barr virus 
EC50 50% Effective concentration 
EC90 90% Effective concentration 
ESI/MS Electrospray ionization mass spectrometry 
EtOAc Ethyl acetate 
EtOH Ethanol 
FMOC 9-fluorenylmethyloxycarbonyl 







HaCat Human Keratinocyte cells 
HBTU O-Benzotriazole-N,N,N‘,N‘-tetramethyl-uronium-hexafluoro-
phosphate                
HCV Hepatitis C virus 
HHV6 Human herpes virus 6 
HIV Human immunodeficiency virus 
HMDS Hexamethyldisilazane 
HOBT N- Hydroxybenzotriazole 
HPV Human papilloma virus 
HSV Herpes simplex virus 
ICT International Committee Taxonomy of viruses 
K/2.2.2. Kryptofix 
K3Fe(CN)6 Potassium ferricyanide  
KH Potassium hydride 
KI Potassium iodide 
KOH Potassium hydroxide 
LiAlH4 Lithium aluminium hydride 
LPC Lisophosphatidylcholine 
MOI Low multiplicity of infection 
MW Microwave 
NA Neuraminidase 
NaB(OAc)3H Sodium triacetoxyborohydride 
NaBH4 Sodium borohydride  
NaH Sodium hydride 
NaIO4 Sodium periodate 
NaOH Sodium hydroxide 












Nuclear Magnetic Resonance 
OsO4 Osmiun Tetroxide 
P.E.T Positron Emission Tomography 
P20H6 Host-guest peptide 
Pb(OAc)4 Lead (IV) acetate 
Pd(PPh3)2OAc Acetate bis(triphenylphosphine) palladium (II) 
PdCl2 Palladium chloride 
PFU Plaque-forming units 
PPh3 Triphenylphosphine 
RP-HPLC Reversed phase- High-performance liquid 
RSV Respiratory syncitial virus 
rt Room temperature 
S.P.E.C.T. Single photon emission computed tomography 
SI Selectivity index 
SPPS Solid phase peptide synthesis 
SS Selectivity Surface 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TIPS Triisopropylsilane 
VZV Varicellazoster virus 
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